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1. Introduction 
Hydrogen sulfide is a chemical compound, made up of two hydrogens and 
one sulfide atom, hence the chemical formula H2S. It is a colorless, flammable, 
water-soluble gas with the odor of rotten eggs.  
The initial observations by Kimura’s group suggesting hydrogen sulfide is a 
biologically relevant signaling molecule have been followed by a myriad of 
studies demonstrating some effect of this gas on virtually every organ system and 
tissue. Growing evidence has shown that in addition to nitric oxide (NO) and 
carbon monoxide (CO), H2S is a third gasotransmitter (Wang, 2002). 
Hydrogen sulfide is now recognized as a ubiquitous gaseous signaling 
molecule that plays important and different roles in the endocrine, neuronal and 
cardiovascular system (Szabo, 2007). 
1.1. H2S chemistry and biology 
Hydrogen sulfide is a gas with a structure very similar to that of water, but 
this is where the similarity ends (Figure 1). The sulfur atom is not nearly as 
electronegative as oxygen so that hydrogen sulfide is much less polar than water. 
 
Figure 1 - Similarity in molecular structure between water (H2O) and hydrogen 
sulfide (H2S) 
2 
 
Because of this, comparatively weak intermolecular forces exist forH2S and 
the melting and boiling points are much lower than they are in water. The boiling 
temperatures of hydrogen sulfide and water are -60.7 and +100.0 °C, respectively 
(Caliendo, 2010).  
Hydrogen sulfide is weakly acidic, dissociating in aqueous solution into 
hydronium cation (H3O
+
) and hydrosulfide anion (HS
-
), which subsequently may 
decompose to H3O
+
 and sulfide ion (S
2-
) (Ka1=1.3 x 10
-7
M, Ka2=1 x 10
-19
M). 
 
Figure 2- Chemical equilibrium of H2S in water 
Under physiological conditions, i.e., at pH 7.4, one-third of hydrogen 
sulfide is undissociated and present in biological fluids as H2S. 
1.2. H2S biosynthesis and metabolism 
In mammalian systems, H2S may be produced by two pyridoxal-5’-
phosphate (PLP)-dependent enzymes (vitamin B6), cystathionine -synthase 
(CBS, EC 4.2.1.22) and cystathionine -lyase (CSE aka CGL, EC 4.4.1.1), as well 
as cysteine aminotransferase (CAT, EC 2.6.1.3) and 3-mercaptopyruvate 
sulfurtransferase (3-MST, EC 2.8.1.2). 
These enzymes are involved in transsulfuration and reverse transsulfuration 
pathways in different capacities and utilize specific substrates (Figure 3). 
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Figure 3 - Biosynthesis and transformation of H2S in mammalian cells. CBS, 
cystathionine -synthase; CSE,cystathionine -lyase; CAT, cysteine 
aminotransferase; MST, 3-mercaptopyruvate sulfurtransferase. 
1.2.1. Enzymatic Production of H2S 
Initially CBS and CSE catalysed reactions were thought to be the primary 
pathways for H2S production. CBS catalyzes the -replacement reaction of 
homocysteine with serine to form cystathionine, thereby irreversibly committing 
this reaction into the transsulfuration pathway (Stipanuk, 2004). 
CSE then catalyzes the -elimination of cystathionine to form cysteine, -
ketobutyrate and NH3. Both CBS and CSE can then generate H2S from cysteine 
via -elimination reactions (Singh, 2009).  
A combination of homocysteine and cysteine constitutes the optimal 
substrate for CBS, generating cystathionine and H2S (Figure 3). 
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Furthermore, CSE is capable of using L-cysteine as the substrate to form 
two gases, H2S and NH3 and pyruvate. The involvement of CSE in other 
elimination reactions includes the catalysis of L-homoserine to form H2O, NH3, 
and 2-oxobutanoate and that of L-cystine to form thiocysteine, pyruvate, and NH3. 
CAT transfers the amine group from cysteine to a keto acid, typically -
ketoglutarate, forming 3-mercaptopyruvate. Subsequent desulfuration of 3-
mercaptopyruvate by 3-MST forms the persulfide, 3-MST-SSH. MST would then 
transfer the sulfur from 3-mercaptopyruvate to sulfite or other sulfur acceptors or 
form elemental sulfur. The direct outcome of the CAT-MST pathway is the 
production of sulfane sulfur (or bound sulfur), not the free form of H2S. H2Swould 
be consequently formed either through reduction of the atomic sulfur or released 
from thiosulfate or persulfides. 
The former requires the presence of reductants (Kabil, 2010) and the latter, 
specific enzymes such as thiosulfate sulphur transferase or thiosulfate reductase 
(Stipanuk, 1982). 
CBS and CSE are cytosolic enzymes. CBS was originally considered to be 
the predominant enzyme for H2S production in the brain, whereas H2S synthesis 
in the heart and vasculature was attributed to CSE (Kimura, 2011). 
Recent studies with improved markers have provided a broader picture of 
enzyme distribution, e.g., CBS in vascular endothelium, CAT and 3-MST in 
vascular endothelium and brain and MST, but not CAT, in vascular smooth muscle 
(Olson, 2010). CAT and 3-MST have been found in both mitochondria and cytosol 
(Kamoun, 2004), although 3-MST may be more localized to the mitochondrial 
matrix (Mikami, 2011). 
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The most commonly used agents to inhibit H2S biosynthesis include 
propargylglycine (PGG), -cyanoalanine (BCA), aminooxyacetic acid (AOAA), 
trifluoroalanine and hydroxylamine (HA) (Szabo, 2007; Whiteman et al., 2011). 
PGG and BCA are claimed to be specific inhibitors of CSE, while AOAA is often 
used as a selective CBS inhibitor. 
1.2.2. Non-enzymatic production of H2S 
A minor endogenous source of H2S is the non-enzymatic reduction of 
elemental sulfur to H2S using reducing equivalents obtained from the oxidation of 
glucose in erythrocytes (Searcy, 1998). Human erythrocytes produce H2S when 
provided with elemental sulfur or inorganic polysulfides.  
Sulfide, via non-enzymatic oxidation, yields thiosulfate. The latter can be 
converted to sulfite by thiosulfate reductase in liver, kidney, or brain tissues or by 
thiosulfate sulfurtransferase in the liver. H2S can also be released from thiosulfate 
and persulfides. Garlic and garlic-derived organic polysulfides induce H2S 
production in a thiol-dependent manner (Benavides, 2007). 
Instead, while garlic has long been felt beneficial as an antioxidant, recent 
evidence suggests that a number of beneficial effects of garlic are derived from 
H2S production. 
Thus far the best characterized naturally occurring H2S-donating compound 
from garlic (Allium sativum) is allicin (diallylthiosulfinate) which decomposes in 
water to a number of compounds, such as diallyldisulfide (DADS) and 
diallyltrisulfide (DATS). 
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1.3. Key enzymes responsible for H2S production 
1.3.1. Cystathionine beta-synthase 
The human enzyme comprises 551 amino acids with a subunit molecular 
weight of ~63 kDa (Kraus, 1986). It is a tetramer, which is prone to aggregation, 
and binds one heme and one PLP per subunit. AdoMet functions as a V-type 
allosteric activator, binds stoichiometrically to each subunit (Taoka, 1999), and 
increases enzyme activity ~2- to 3-fold (Figure 4).  
The catalytic core represents the conserved part of the protein and resembles 
other members of the - or fold II class of PLP-dependent enzymes (Alexander, 
1994). The presence of protoporphyrin IX in cystathionine -synthase is unique in 
the family of PLP-dependent enzymes and is seen in only a subset of organisms. 
A glycine rich loop, G256–T257–G258–G259–T260, another conserved 
structural feature of fold II enzymes, makes multiple electrostatic interactions with 
the phosphate moiety of PLP (Figure 5). Based on the chemical shift of the 
enzyme-bound PLP in yeast and human cystathionine-synthase, the phosphate 
appears to be bound as a dianion (Kabil, 2001). 
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Figure 4 - Cristal structure of dimeric human cystathionine-synthase lacking the 
C-terminal regulatory. The figure was generated using the PDB file 1M54. The 
heme is shown in red and the PLP in yellow.  
 
Figure 5 -Close up of the active site of human cystathionine -synthase showing 
the conserved residues that interact with the PLP. 
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The human cystathionine -synthase catalyzes the condensation of serine and 
homocysteine to give cystathionine and H2O. Furthermore, the -elimination 
reaction catalyzed by cystathionine--synthase has the potential for generating 
also H2S, using homocysteine and cysteine as substrates (Figure 6). 
 
Figure 6 - Reactions catalysed by CBS. 
1.3.2. Cystathionine gamma-lyase  
The three-dimensional structures of human and yeast CSE have recently 
been elucidated via X-ray crystallography (Sun, 2009). 
Structurally, the enzyme consists of four identical monomers of 
approximately 45 kDa, with a covalently bound pyridoxal 5′-phosphate (PLP) 
cofactor in each monomer (Figure 7). However, some studies show evidence for 
differential PLP binding affinities among the monomers of CSE and transient 
dissociation or removal of PLP from the enzyme during the catalytic process 
(Messerschmidt, 2003). 
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Figure 7 - Cristal structure of human cystathionine -lyase. The figure was 
generated using the PDB file 2NMP. The PLP is shown in pink.  
Based on the crystal structures of yeast and human CSE as well as on 
sequence alignment with other transsulfuration enzymes, several active-site 
residues that could be involved in catalyzing the α,β-elimination reaction, leading 
to H2S production, were identified (Huang, 2010). 
In the crystal structures of yeast and human CSE, several residues were 
found to contribute towards the binding of the PLP cofactor. These residues 
include Tyr60 and Arg62 from the adjacent monomer; Tyr114, which π-stacks 
with the pyridoxal ring of the cofactor; Asp187, which hydrogen bonds to the 
pyridoxal nitrogen; and Ser209 and Thr211, which provide hydrogen-bond 
contacts to the phosphate group. Studies have also shown that Lys212 serves as an 
important catalytic residue by forming a covalent bond to the PLP cofactor and 
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facilitating proton transfer reactions during the α,γ-elimination reaction of L-
cystathionine. 
The location of the residues (only side chains shown) studied by site-
directed mutagenesis is shown in Figure 8, and significant hydrogen bonds and 
polar interactions are depicted by dotted lines. Besides interacting with residues 
from the same subunit, the PLP cofactor is hydrogen bonded to Tyr60
⁎
 and Arg62
⁎
 
from the adjacent subunit as well. The figure was produced by the program 
PyMOL (DeLano, 2002). 
 
Figure 8- Active site of the human CSE enzyme.  
CSE is an enzyme that is found predominantly in mammals and some fungi 
and is traditionally known for its role in the reverse transsulfuration pathway, 
where L-methionine is converted into L-cysteine through a series of metabolic 
interconversions. 
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Figure 9- Reactions catalysed by CSE.  
Specifically, the role of CSE in this reaction pathway is to convert L-
cystathionine into L-cysteine whilst generating α-ketobutyrate and ammonia 
(Figure 9). The reaction proceeds via an α,γ-elimination mechanism where the C–
γ–S bond of L-cystathionine is specifically cleaved to yield L-cysteine. 
Besides its role in the conversion of L-cystathionine into L-cysteine, studies 
have also shown that CSE can utilize L-cysteine as a substrate for producing H2S 
via an α,β-elimination reaction (Figure 9). 
1.4. Biological functions of hydrogen sulfide 
Knowledge of the biological roles for endogenous H2S is constantly 
expanding. Many studies in the literature indicate that H2S executes physiological 
effects at a wide range of concentrations between 10 and 300 M (Li, 2011). 
It is clear that H2S is involved in modulating various physiological 
responses including anti-inflammation (Zanardo, 2006), reducing oxidative stress 
(Yonezawa, 2007), neuromodulation (Abe, 1996), vasoregulation (Laggner, 2007), 
protection from reperfusion injury after myocardial infarction (Sivarajah, 2009), 
and inhibition of insulin resistance (Ali, 2007). 
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Moreover, many researchers continue to explore this signalling molecule for 
its involvement in various aspects of cell function, cytoprotection and cellular 
signalling. 
1.4.1. Cardiovascular system 
The growing knowledge about the biological significance of H2S in the 
heart and blood vessels is unravelling the importance of this gaseous mediator in 
the control of CV homeostasis. 
In particular, it is emerging that H2S shares almost all the beneficial effects 
of NO, without being the source of toxic metabolites (Lefer, 2007). Recently, it 
has been proposed that the role of H2S in CV homeostasis becomes more 
important and critical, when the NO-mediated control is compromised (for 
example, in the case of endothelial dysfunction). H2S evokes relaxing responses in 
the vascular smooth muscle, and this action has been observed in large vessels, 
such as the rat thoracic aorta and portal vein, as well as (and with higher potency) 
in peripheral resistance vessels, which play a more significant role than large 
conduit arteries in the regulation of vascular resistance and blood pressure 
(Cheng, 2004). The vasomotor effects of H2S are mimicked by L-cysteine and the 
vasorelaxing activity of L-cysteine is abolished by the CSE inhibitor PGG, thus 
proving that L-cysteine acts as a H2S source. Consistently, genetic deletion of 
CSE in mice markedly reduces H2S levels in the serum, heart, and aorta, and 
mutant mice lacking CSE develop marked hypertension and a decreased 
endothelium-dependent vasorelaxant effect (Yang, 2008). 
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It is currently acknowledged that H2S relaxes blood vessels mainly (not 
exclusively) by opening the KATP channels of vascular smooth muscle cells. 
Together with vasorelaxing activity, H2S (such as NO) is endowed with a wide 
range of additional biological roles, which are relevant for a polyedric control of 
the CV system. For example, H2S inhibits platelet aggregation/adhesion induced 
by ADP, collagen, epinephrine, arachidonic acid, thromboxane mimetic U46619, 
and thrombin. 
1.4.2. Immune system and inflammation 
It is well known that nonsteroidal anti-inflammatory drugs (NSAIDs) induce 
gastroenteropathy (Fiorucci, 2005). Research suggests that NSAIDs suppressed 
endogenous H2S synthesis by reducing expression of CSE. 
The accompanying reduction of H2S synthesis may in turn contribute to an 
increase in leukocyte adherence resulting in gastric injury that is seen after 
NSAID administration (Perini, 2004). 
Similarly, administration of exogenous H2S reduced the ability of these 
agents to cause gastric injury. Exogenously supplied H2S suppressed NSAID-
induced granulocyte infiltration, expression of endothelial and leukocyte adhesion 
molecules, and expression of tumor necrosis factor  (TNF) (Fiorucci, 2005). It 
was found that leukocyte adhesion to the vascular endothelium induced by aspirin 
injury was decreased after increasing H2S bioavailability and that CSE inhibition 
with propargylglycine exacerbated aspirin mediated mucosal injury and 
inflammation. This study also observed that leukocyte expression of LFA-1 was 
suppressed by exogenous H2S. Interestingly, this article also showed a molecular 
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aspect of H2S induced anti-inflammatory effects, such that H2S donors decreased 
aspirin-induced leukocyte adhesion through the activation of KATP channels and 
inhibition of CSE activity that promotes leukocyte adhesion. Additional studies 
demonstrated that co-administration of an H2S donor with an NSAID resulted in 
inhibition of NSAID-induced leukocyte adherence and reduction of the severity of 
gastric damage (Wallace, 2007). 
1.4.3. Respiratory system 
The major environmental exposure to H2S in humans is through the 
respiratory tract. On the basis of the H2S relaxing action on the vascular smooth 
muscle, the relaxant property of H2S has been investigated also on rings of 
bronchial smooth muscle of two rodent species. This study showed that H2S 
causes strong relaxation in the isolated bronchus rings from the mouse, but 
produces only slight relaxation in guinea pig rings.  
H2S content and CSE activity are significantly enhanced also in isolated rat 
lung submitted to ischemia/reperfusion injury, and a preventive perfusion with 
H2S attenuates such an injury, reducing malondyaldehyde (MDA) production and 
stimulating superoxide dismutase and catalase activity (Fu, 2008). 
Concerning the endogenous CSE/H2S pathway, it seems to play a relevant 
role in pulmonary hypertension (PH). In particular, this pathway has been found to 
be down-regulated in hypoxic PH (HPH), resulting in a decreased endogenous 
H2S production in rat lung tissues due to oxidative stress. In particular, both the 
gene expression of CSE and the activity of this enzyme were suppressed in lung 
tissues during HPH, but the exogenous supply of H2S resulted in enhancing CSE 
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activity, upregulating CSE gene expression in lung tissue and lessening pulmonary 
vascular structure remodeling during HPH (Zhang, 2003). After the treatment with 
exogenous H2S, HPH was attenuated, through a direct scavenging of oxidized 
glutathione (GSSG), an increased total antioxidant capacity (Wei, 2008) and the 
inhibitory effect of H2S on pulmonary vascular inflammation, associated with a 
high I-B (inhibitor of NF-B) expression and a down-regulation of NF-B p65 
expression (Jin, 2008). 
Furthermore, The CSE/H2S pathway seems to exert beneficial roles also in 
the two most important obstructive airway diseases, such as asthma and chronic 
obstructive pulmonary disease (COPD). In an ovalbumin-induced asthmatic rat 
model and in human asthmatic patients, the levels of endogenous H2S, whose anti-
inflammatory effects are related to the inhibition of iNOS activity and decrease 
with the progression of disease severity (Fan, 2009). Consistently, increased levels 
of serum H2S in milder COPD may play a useful role in airway protection, 
antagonizing oxidative stress and airway inflammation and preventing the 
progress of COPD. 
1.4.4. Reproductive system 
Recent studies focused on the effects of exogenous H2S on mammalian 
reproductive systems. The powerful vasorelaxant effect of H2S on the penile 
artery suggests an important physiological role of H2S in the erectile response of 
human corpus cavernosum (Di Villa Bianca, 2009). 
Specifically, NaHS (0.1–1 mM) relaxed the preconstricted human corpus 
cavernosum strips in vitro, independent of the presence of endothelium or the 
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function of endothelial NOS (eNOS). The relaxant effect of NaHS depends on the 
nature of the stimuli that were used to preconstrict the tissue strips. 
1.4.5. Central Nervous System 
As an almost ubiquitous bioactive molecule, H2S exerts important 
regulatory effects in several biological systems. For instance, it is pivotally 
involved in the control of important functions in the CNS. A high expression of 
CBS in the rat hippocampus and cerebellum was observed (Abe, 1996).  
In CNS neurons, H2S enhances cAMP production, thus leading to an 
increased sensitivity of NMDA receptors to glutamate (Kimura, 2000). 
This sensitization of NMDA receptors, elicited by quite high concentrations 
of H2S (50–160 M), contributes to the induction of hippocampal long-term 
potentiation, a process of synaptic plasticity involved in the mechanisms of 
learning and memory (Kimura, 2005). Increased production of cAMP activates 
protein kinase A which regulates brain function through intracellular protein 
phosphorylation, but this is not the only intracellular signalling in which H2S 
seems to be involved. 
 In fact, H2S may enhance reducing activity and protect neurons against 
oxidative stress via activation of upstream receptor tyrosine kinase (Tan, 2010). 
Finally, recent findings reported that H2S inhibits lipopolysaccharide(LPS)-
induced NO production in microglia via inhibition of p38-MAPK (Hu, 2010) and 
that MAPKs regulate cellular activities, such as apoptosis, differentiation, 
metabolism, etc (Roux, 2004). These data suggest a role for H2S in the treatment 
of cerebral ischemia and neuro-inflammatory diseases. 
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2. Aim of project 
Retrospective analysis of the literature on biological effects of H2S suggests 
two approaches for studying physio-pathological conditions in which it is 
involved and for the developing therapies based on its activities: 
• use of H2S in the gaseous state, or "sulfur-precursors" or "prodrugs" capable 
of releasing, directly or via interaction with specific enzymes, hydrogen 
sulfide; 
• use of CBS/CSE inhibitors, leading to blockade of endogenous production 
of H2S. 
The aim of my PhD project is design, synthesis and structural 
characterization of three different series of compounds: 
1. CBS/CSE substrates a/o inhibitors, crucial to study the pathophysiological 
implications of H2S; 
2. hydrogen sulfide-releasing hybrids, containing pharmacologically active 
compounds and molecules able to release H2S, that could enhance 
therapeutic activity; 
3. novel compounds able to release H2S, non enzimatically, with slow kinetic 
of release, mimicking the physiological conditions. 
Because of the unavailability of a pharmacophoric model as a lead for 
rational design of targeted enzyme substrates and inhibitors we preliminarily 
selected and tested commercially available cysteine surrogates. The catalytic 
profiles of recombinant CBS and CSE were assessed in the presence of the 
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following selected compounds: L-(S-carbamoyl)-cysteine; L-2-oxothiazolidin-4-
carboxylic acid; L-3-(2-aminoethylthio)-2-aminopropanoic acid; L-thiazolidine-4-
carboxylic acid;  D,L-penicillamine. 
On the basis of the obtained results, new compounds were designed; they 
were characterized by the introduction of a propargyl group in -carboxyl 
position, aiming to obtain novel molecular entities embodying the structural 
features of both cysteine and the well known CSE inhibitor, DL-propargylglycine 
(PGG). In order to consider the small size of the active site channel, containing 
several patches of hydrophobic residues, we decided to introduce a butyl group in 
-carboxyl position, to facilitate the access to the enzyme active site.  
The structural modifications were also extended to aromatic scaffolds, to 
weaken -stacking interaction between PLP and Tyr114, two important 
components of the active site (Table 1). 
Further development of my PhD project is related to new classes of 
hydrogen sulfide-releasing moieties combined with pharmacologically active 
compounds. In particular, my attention has been paid to the synthesis of hydrogen 
sulfide-releasing hybrids, such as glucocorticoids-H2S donors.  
With regard to glucocorticoids, the choice is derived from the analysis of a 
recent in vivo study that investigated the effects of a H2S donor (NaHS) on 
airways in balb/c mice sensitized with ovalbumin (OVA) (Roviezzo et al., 
submitted). In this study, aerosolized NaHS blunted OVA-induced airway 
hyperesponsiveness: these data suggest that combined early treatment with H2S 
donors in association with glucocorticoids might improve asthma symptoms by 
inhibiting classical inflammatory signals and by acting, at the same time, on 
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airway myofibroblasts, perhaps delaying the onset of sub-epithelial fibrosis and 
the secretion of inflammatory factors and contributing to bronchodilation. 
Considering the vast potential of hydrogen sulfide in asthma therapy, we 
have supposed that combined treatment with glucocorticoids and H2S-releasing 
moieties could represent an effective therapeutic strategy for asthma care. 
Starting from this consideration, glucocorticoids-H2S donors have been 
designed: two most commonly used corticosteroids, dexamethasone and 
beclomethasone, were condensed with different H2S-releasing compounds, such 
as 5-(p-hydroxyphenyl)-1,2-dithione-3-thione (ADT-OH) and 4-hydroxy-
thiobenzamide (TBZ) (Table 2). 
Concerning the third class of compounds, H2S-releasing capacity is a 
pharmacologically relevant feature, already attributed to naturally occurring 
compounds, such as the diallyl polysulfides of garlic and our attention was thus 
devoted to the synthesis of ureic derivatives, as well as 1,2,4-thiadiazolidine-3,5-
diones, representing a potential innovative scaffold for the release of H2S (Table 
3). These derivatives, in analogy with the N-(benzoylthio)benzamide compounds, 
recently reported in the literature, were evaluated according to their ability to 
release H2S following the cleavage of the NH-S bond. 
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3. Materials and methods 
3.1. Chemistry 
The synthetic route for the preparation of propargylamide (Ia-IIIa) and 
butylamide (Ib-IIIb) derivatives is reported in Scheme 1. The carboxylic acid 
was treated with N-(9-fluorenylmethoxycarbonyloxy) succinimide to protect the 
amine group, if needed. The coupling reaction of N-protected carboxylic acid with 
opportune amine, propargylamine hydrochloride or butylamine, was performed in 
the presence of TBTU, HOBt and N,N-diisopropylethylamine (DIPEA), leading 
to the formation of an amide bond. Fmoc deprotection, when necessary, was 
carried out using a solution of 33% DIEA in tetrahydrofuran, obtaining 
compounds Ia-IIIa and Ib-IIIb, respectively. 
The general strategy for the synthesis of compounds IVa-IVb is 
summarized in Scheme 2, as follows: protection of amine and carboxyl groups; 
ether formation using the conventional Williamson synthesis, by treatment with a 
strong base,  NaH or Na2CO3, and propargyl bromide or butyl bromide, 
respectively, performed in anhydrous CH3CN; subsequent Boc deprotection and 
methyl esther hydrolysis, providing the final compounds IVa and IVb.  
Scheme 3 depicts the synthetic pathways employed to prepare 
glucocorticoids-H2S donors. Glucocorticoids, dexamethasone or beclomethasone, 
were converted to the corresponding 21-succinate by treatment with succinic 
anhydride in the presence of catalytic amount of DMAP in anhydrous pyridine. 
Coupling reaction of succinate derivative with H2S releasing chemical moieties, 
such as ADT-OH or 4-hydroxythiobenzamide (TBZ), was performed in the 
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presence of EDC and DMAP, leading to the formation of glucocorticoids 
derivatives (FAS I-IV). 
The synthetic strategy employed for the preparation of the 1,2,4-
thiadiazolidin-3,5-dionesis summarized in Scheme 4. The compounds (THIA I-
VII) were synthesized through oxidative condensation of isothiocyanates with 
isocyanates in the presence of SO2Cl2 as the oxidizing agent. 
 
Scheme 1- i) Na2CO3 9% /Fmoc-OSu/dioxane; ii) TBTU/HOBt/DIPEA; iii) 33% 
DIEA in THF. 
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Scheme 2- i) di-t-butyl dicarbonate/triethylamine/H2O/dioxane; ii) DCC/MeOH; 
iii) potassium carbonate/acetonitrile; propargylamine hydrochloride; iv) sodium 
hydride/anhydrous acetonitrile; butylamine; vi) 1N sodium hydroxide 
solution/ethanol; vii) 40% trifluoroacetic acid in dicloromethane solution.  
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Scheme 3- i) succinic anhydride/DMAP/anhydrous pyridine; ii) EDC/DMAP 
 
 
 
Scheme 4- i) SOCl2/diethyl ether; ii) H2O, reflux 
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3.2. Experimental procedures 
All reagents were commercial products purchased from Sigma Aldrich. 
Melting points, determined using a Buchi Melting Point B-540 instrument, are 
uncorrected and represent values obtained on recrystallized or 
chromatographically purified material. 
1
H-NMR spectra were recorded on Varian 
Mercury Plus 400 MHz instrument. Unless otherwise stated, all spectra were 
recorded in DMSO. Chemical shifts are reported in ppm using Me4Si as internal 
standard. The following abbreviations are used to describe peak patterns when 
appropriate: s (singlet), d (doublet), t (triplet), q (quartet), qt (quintet), dd (double 
doublet), m (multiplet). Mass spectra of the final products were performed on API 
2000 Applied Biosystem mass spectrometer. Elemental analyses were carried out 
on a Carlo Erba model 1106; analyses indicated by the symbols of the elements 
were within ±0.4% of the theoretical values. All reactions were followed by TLC, 
carried out on Merck silica gel 60 F254 plates with fluorescent indicator and the 
plates were visualized with UV light (254 nm). Preparative chromatographic 
purifications were performed using silica gel column (Kieselgel 60). Solutions 
were dried over Na2SO4 and concentrated with a Buchi R-114 rotary evaporator at 
low pressure. 
3.2.1. Cysteine surrogates: propargylamide and n-butylamide 
derivatives (Ia-IIIa and Ib-IIIb) 
3.2.1.1. 3-(((9H-fluoren-9-yl)methoxy)carbonyl)thiazolidine-4-carboxylic acid 
(1a).The thiazolidine-4-carboxylic acid (1, 1g, 7.5mmol) in Na2CO3 9% (10 mL) 
was cooled in ice water and mechanically stirred. Then a solution of Fmoc-OSu 
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(2.5g, 7.5mmol) and dioxane (20 mL) was added dropwise and the mixture was 
stirred for 2.5 hours at room temperature. The solvent was evaporated, the 
aqueous residue acidified with 1N HCl and the product extracted with ethyl 
acetate. The organic phase was then dried on anhydrous Na2SO4 and filtered, and 
the solvent was evaporated. The product was crystallized from diethyl ether, 
yielding 2.5 g of 3-(((9H-fluoren-9-yl)methoxy)carbonyl)thiazolidine-4-
carboxylic acid (1a, 94%) as a solid. 
3.2.1.2. N-(prop-2-yn-1-yl)thiazolidine-4-carboxamide and N-butylthiazolidine-4-
carboxamide (Ia and Ib). The intermediate 3-(((9H-fluoren-9-
yl)methoxy)carbonyl)thiazolidine-4-carboxylic acid (1a, 1g, 2.8mmol) was 
dissolved in DMF (30mL) and coupled to the opportune amine, propargylamine 
hydrochloride (0.258g, 2.8mmol) or butylamine (0.205g, 2.8mmol), in the 
presence of DIPEA (0.536mL, 3.1mmol), using HOBt (0.472g, 3.1mmol) and 
TBTU (0.988g, 3.1mmol) as the coupling reagents. This reaction was carried out 
at room temperature with stirring overnight. The solvent was evaporated, and the 
crude material was then dissolved in ethyl acetate (150mL) and washed with 5% 
citric acid  (3 x 50mL), 10% NaHCO3 (3 x 50mL) and brine (50mL). The organic 
layer was dried on anhydrous Na2SO4 and filtered, and the solvent was 
evaporated. After chromatography on a silica gel column (eluent, 7:3 ethyl 
acetate/hexane) 0.86 g and 0.82 g of intermediates I were obtained (82% for the 
propargylamide derivative and 75% for the n-butylamide derivative, respectively) 
as solids.  
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Fmoc deprotection of intermediates I was performed using a 33% diethylamine 
solution in tetrahydrofuran and the mixture was stirred for 2.5 hours at room 
temperature. Afterward the solvent was concentrated in vacuo and the obtained 
residue was purified by column chromatography (dichloromethane/methanol 
9.5:0.5 (v/v)). The combined and evaporated product fractions were crystallized 
from hexane, to give the final compounds N-(prop-2-yn-1-yl)tiazolidin-4-
carboxamide Ia and N-butylthiazolidine-4-carboxamide Ib as white solids 
(obtained yields 72% and 70% respectively).  
N-(prop-2-yn-1-yl)thiazolidine-4-carboxamide (Ia) mp 126−127 °C; 1H NMR 
(400 MHz, DMSO-d6) 3.13 (s, 1H, CCH),3.10-3.18 (dd, 1H, CH2CH thiaz, 
J=6.65), 3.39-3.43 (dd, 1H, CH2CH thiaz, J=6.65),3.88 (s, 2H, NHCH2),  3.96 (d, 
1H, SCH2NH, J=9.90), 4.13 (t, 1H, CH2CH thiaz), 4.24 (d, 1H, SCH2NH, J=9.90), 
8.29 (s, 1H, NH), 8.99 (s, 1H, NH); 
13
C NMR (400 MHz, DMSO-d6) 29.0, 
32.9,61.8, 74.0, 74.6, 81.3,170.1; ESI-HRMS (M + H)
+ 
m/z calcd 170.23 for 
C7H10N2OS; found 171. 
N-butylthiazolidine-4-carboxamide (Ib) mp 126−127 °C; 1H NMR (400 MHz, 
DMSO-d6) 0.91 (t, 3H, CH3, J=6.96, J=7.33), 1.30-1.36 (m, 2H, CH2CH3), 1.46-
1.51 (qt, 2H, CH2CH2CH3, J=6.65, J=7.04, J=7.43, J= 7.04), 3.10-3.18 (dd, 1H, 
CH2CH thiaz, J=6.65), 3.25 (t, 2H, CH2CH2CH2CH), 3.39-3.43 (dd, 1H, CH2CH 
thiaz, J=6.65), 3.96 (d, 1H, SCH2NH, J=9.90), 4.13 (t, 1H, CH2CH thiaz), 4.24 (d, 
1H, SCH2NH, J=9.90), 8.29 (s, 1H, NH), 8.99 (s, 1H, NH); 
13
C NMR (400 MHz, 
DMSO-d6) 14.1, 19.9, 31.5, 32.8, 38.9, 61.8, 74.6, 170.1; ESI-HRMS (M + H)
+ 
m/z calcd 188.29 for C8H16N2OS; found 189. 
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3.2.1.3. 2-oxo-N-(prop-2-yn-1-yl)thiazolidine-4-carboxamide and N-butyl-2-
oxothiazolidine-4-carboxamide (IIa and IIb). A mixture of 2-oxo-N-thiazolidine-
4-carboxilic acid 2 (1g, 6.8mmol), the opportune amine, propargylamine 
hydrochloride (0.622g, 6.8mmol) or butylamine (0.497g, 6.8mmol), HOBt (1.15g, 
7.5mmol), TBTU (2.40g, 7.5mmol) and DIPEA (1.30mL, 7.5mmol) in DMF 
(20mL) was stirred overnight at room temperature. The solvent was concentrated 
to dryness and the crude mixture was purified by silica gel column 
chromatography using ethyl acetate/hexane 7:3 (v/v) as eluent. The crude product 
was recrystallized from hexane, yielding 0.96 g of 2-oxo-N-(prop-2-yn-1-
yl)thiazolidine-4-carboxamide IIa (76%) and 0.94 g of N-butyl-2-oxothiazolidine-
4-carboxamide IIb (69%), respectively. 
2-oxo-N-(prop-2-yn-1-yl)thiazolidine-4-carboxamide (IIa) mp 131.5−132.4 °C; 
1
H NMR (400 MHz, DMSO-d6) 3.13 (s, 1H, CCH), 3.31 (t, 2H, CH2), 3.62-3.68 
(dd, 2H, CH2 thiaz, J=8.61), 3.88 (s, 2H, NHCH2), 4.27 (t, 1H, CH2CH thiaz), 
8.27 (s, 1H, NH), 8.53 (s, 1H, NH); 
13
C NMR (400 MHz, DMSO-d6)  29.0, 32.9, 
56.8, 74.0, 81.3, 170.6, 174.0; ESI-HRMS (M + H)
+ 
m/z calcd 184.22 for 
C7H8N2O2S; found 184.9. 
N-butyl-2-oxothiazolidine-4-carboxamide (IIb) mp 83.2-83.7 °C; 
1
H NMR (400 
MHz, DMSO-d6); 0.85 (t, 3H, CH3, J=7.04, J=7.43), 1.21-1.30 (m, 2H, 
CH2CH3), 1.34-1.41 (qt, 2H, CH2CH2CH3, J=6.65, J=7.04, J=7.43, J= 7.04), 3.04-
3.09 (dd, 1H, CH2CH thiaz, J=6.65), 3.60-3.65 (dd, 1H, CH2CH thiaz, J= 8.61), 
4.22 (t, 1H, CH2CH thiaz), 7.99 (s, 1H, NH), 8.23 (s, 1H, NH); 
13
C NMR (400 
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MHz, DMSO-d6)  14.1, 19.9, 31.5, 32.8, 38.9, 56.9, 170.1, 173.7; ESI-HRMS 
(M + H)
+ 
m/z calcd 202.27 for C8H14N2O2S; found 203.0. 
3.2.1.4. 2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(thiophen-2-yl)propa-
noic acid (3a).The 2-amino-3-(thiophen-2-yl)propanoic acid (3, 1g, 5.8mmol) in 
Na2CO3 9% (10mL) was cooled in ice water and mechanically stirred. Then a 
solution of Fmoc-OSu (1.97g, 5.8mmol) and dioxane (20mL) was added dropwise 
and the mixture was stirred for 2.5 hours at room temperature. The solvent was 
evaporated, the aqueous residue acidified with 1N HCl and the product extracted 
with ethyl acetate. The organic phase was then dried on anhydrous Na2SO4 and 
filtered, and the solvent was evaporated. The product was crystallized from 
diethyl ether, yielding 2.08 g of 2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-
(thiophen-2-yl)propanoic acid (3a; 91%) as a solid. 
3.2.1.5. 2-amino-N-(prop-2-yn-1-yl)-3-(thiophen-2-yl)propanamide and 2-amino-
N-butyl-3-(thiophen-2-yl)propanamide (IIIa and IIIb).The intermediate 2-(((9H-
fluoren-9-yl)methoxy)carbonylamino)-3-(thiophen-2-yl)propanoic acid (3a, 1.0g, 
2.5mmol) was dissolved in DMF (30mL) and coupled to the opportune amine, 
propargylamine hydrochloride (0.229g, 2.5mmol) or butylamine (0.183g, 
2.5mmol), in the presence of DIPEA (0.48mL, 2.8mmol), using HOBt (0.42g, 
2.8mmol) and TBTU (0.885g, 2.8mmol) as the coupling reagents. This reaction 
was carried out at room temperature with stirring overnight. The solvent was 
evaporated, and the crude material  was then dissolved in ethyl acetate (150 mL) 
and washed with citric acid 5% (3 x 50 mL), NaHCO3 10% (3 x 50 mL) and brine 
(50 mL). The organic layer was dried on anhydrous Na2SO4 and filtered, and the 
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solvent was evaporated. After chromatography on a silica gel column (eluent, 7:3 
ethyl acetate/hexane) 0.90 g and 0.98 g of intermediates III were obtained (76% 
for the propargylamide derivative and 87% for the n-butylamide derivative, 
respectively) as solids. A solution of 33% diethylamine solution in 
tetrahydrofuran was used during deprotection of Fmoc group of intermediates III. 
The mixture was stirred for 2.5 hours at room temperature. Afterward the solvent 
was concentrated in vacuo and the obtained residue was purified by column 
chromatography (dichloromethane/methanol 9.5:0.5 (v/v)). The combined and 
evaporated product fractions were crystallized from hexane, to give the final 
compounds N-(prop-2-yn-1-yl)tiazolidin-4-carboxamide IIIa and 2-amino-N-
butyl-3-(thiophen-2-yl)propanamide IIIb as white solids (yield: 68% and 75%, 
respectively). 
2-amino-N-(prop-2-yn-1-yl)-3-(thiophen-2-yl)propanamide (IIIa). mp 196.2-
196.3°C; 
1
H NMR (400 MHz, DMSO-d6) s, 1H), 3.27-3.31 (dd, 2H, 
CH2CH, J=6.06), 3.90 (s, 2H, NHCH2), 3.95 (t, 1H, CHCO, J=6.09), 6.94-6.97 
(m, 2H, H-thioph), 7.40 (d, 1H, H-thioph, J=3.9), 8.38 (s, 2H, NH), 9.05 (s, 1H, 
NH2); 
13
C NMR (400 MHz, DMSO-d6)  28.9, 31.4, 53.9, 74.6, 80.7, 126.4, 
127.9, 128.4, 136.4, 168.0; ESI-HRMS (M + H)
+ 
m/z calcd 208.28 for 
C10H12N2OS; found 209.2. 
2-amino-N-butyl-3-(thiophen-2-yl)propanamide (IIIb). mp 172.9-173.3°C; 
1
H 
NMR (400 MHz, DMSO-d6)0.85 (t, 3H, CH3, J=7.04, J=7.43), 1.21-1.30 (m, 
2H, CH2CH3), 1.34-1.41 (qt, 2H, CH2CH2CH3, J=6.65, J=7.04, J=7.43, J= 7.04), 
3.20 (d, 2H, NHCH2 J= 6.03), 3.27-3.31 (dd, 2H, CH2CH, J=6.06),3.95 (t, 1H, 
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CHCO, J=6.09),6.94-6.97 (m, 2H, H-thioph), 7.40 (d, 1H, H-thioph, J=3.9), 8.38 
(s, 2H, NH), 9.05 (s, 1H, NH2);
13
C NMR (400 MHz, DMSO-d6)  14.1, 19.9, 
31.4, 38.9, 53.9, 56.9, 126.4, 127.9, 128.4, 136.4, 168.0; ESI-HRMS (M + H)
+ 
m/z calcd 226.34 for C11H18N2OS; found 227.0. 
3.2.1.6.Methyl 5-(tert-butoxycarbonylamino)-2-hydroxybenzoate (6). To a solution 
of 5-amino-salicylic acid (4, 2g, 13.0mmol) in 25 ml of dioxane and 12.5 mL of 
water, triethylamine (2.6mL, 19.5mmol) and di-tert-butyl-dicarbonate (4.2g, 
19.5mmol) were added with stirring at 0° C for 1/2 h. The reaction mixture was 
stirred mechanically for 24 h at room temperature. After evaporation of the 
solvent, 3N HCI (15mL) was added dropwise to the residue. The precipitate is 
filtered, washed with water, dried and recrystallized from diethyl ether. 5-(tert-
butoxycarbonylamino)-2-hydroxybenzoic acid was obtained (5) (3.28g, 100 % 
yield) and the powder (5, 3g, 11.8mmol) was dissolved in anhydrous methanol. To 
the solution, cooled to 0 °C, dicyclohexylcarbodiimide (2.4g, 11.8mmol) was 
added and the mixture was stirred at room temperature for 3h. The solvent was 
evaporated, the residue was taken up in ethyl acetate and dicyclohexylurea (DCU) 
was filtered. After chromatography on a silica gel column (eluent, 7:3 ethyl 
acetate/hexane) 2.3 g of 6 was obtained (73%) as a white solid. 
3.2.1.7. 5-amino-2-(prop-2-ynyloxy)benzoic acid (IVa). Intermediate 6 (1g, 
4.0mmol) in anhydrous acetonitrile was treated with potassium carbonate (0.475g, 
4.0mmol) and then propargyl bromide (solution 80% wt. in toluene) (0.446mL, 
4.0mmol) was added slowly into the flask. The reaction mixture was stirred under 
reflux overnight. After this period, carbonate was filtered and solvent concentrated 
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in vacuo. The residue was purified by column chromatography (3:7 ethyl 
acetate/hexane (v/v)). The combined and evaporated product fractions were 
crystallized from diethyl ether/hexane, affording 0.734g (62% yield) of methyl 5-
(tert-butoxycarbonylamino)-2-(prop-2-ynyloxy)benzoate (7). 
To a solution of obtained compound (7, 0.734g, 2.5mmol) in ethanol, sodium 
hydroxide was added and the mixture was mechanically stirred at room 
temperature for 2 hours. The solvent was removed in vacuo and residue was 
slightly acidified with 1N hydrochloric acid. The aqueous solution was extracted 
with ethyl acetate and the organic phase was dried over anhydrous Na2SO4, 
filtered and evaporated to dryness to afford 0.734 g of compound 9 as a white 
powder (100% yield). 
The crude intermediate (9, 0.734g, 2.5mmol) was treated with a solution of 40 % 
TFA in DCM. After 2 h the solvent was removed to obtain the crude product. The 
residue was loaded on a silica gel open column and eluted with ethyl 
acetate/hexane (7:3 v/v). The combined and evaporated fractions were crystallized 
from hexane to yield 0.386 g (87%) of pure product IVa. mp 220.0-220.4°C; 
1
H 
NMR (400 MHz, DMSO-d6); 3.48 (s, 1H, CH), 4.63 (s, 2H, CH2), 6.69 (d, 1H, 
J=8.43, Ar-H), 6.89 (d, 1H, J=8.43, Ar-H), 6.91 (s, 1H, Ar-H); 
13
C NMR (400 
MHz, DMSO-d6) 58.43 78.69, 80.50, 116.55, 118.35, 118.88,123.74, 143.42, 
148.11, 168.04; ESI-HRMS (M + H)
+ 
m/z calcd 191.18 for C10H9NO3; found 192. 
3.2.1.8. 5-amino-2-butoxybenzoic acid (IVb). Intermediate 6 (1g, 4.0mmol) in 
anhydrous acetonitrile was treated with sodium hydride (0.097g, 4.0mmol) and 
then 1-butyl bromide (0.410 mL, 4.0mmol) was added slowly into the flask. The 
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reaction mixture was stirred under reflux overnight. The solvent was concentrated 
in vacuo and the crude material was then dissolved in ethyl acetate (150 mL) and 
washed with citric acid 5% (3 x 50 mL), NaHCO3 10% (3 x 50 mL) and brine (50 
mL). The organic layer was dried on anhydrous Na2SO4 and filtered, and the 
solvent was evaporated. The residue was purified by column chromatography (2:8 
diethyl ether/hexane (v/v)). The combined and evaporated product fractions were 
crystallized from diethyl ether/hexane, affording 0.957 g (74% yield) of methyl 2-
butoxy-5-(tert-butoxycarbonylamino)benzoate (8). 
To a solution of the obtained compound (8, 0.957g, 2.74mmol) in ethanol, sodium 
hydroxide was added and the mixture was mechanically stirred at room 
temperature for 2 hours. The solvent was removed in vacuo and residue was 
slightly acidified with 1N hydrochloric acid. The aqueous solution was extracted 
with ethyl acetate and the organic phase was dried over anhydrous Na2SO4, 
filtered and evaporated to dryness to afford 0.908 g of 2-butoxy-5-(tert-
butoxycarbonylamino)benzoic acid (10) as a white powder (99% yield). 
The crude intermediate (10, 0.908g, 2.9mmol) was treated with a solution of 40 % 
TFA in DCM. After 2 h the solvent was removed to obtain the crude product. The 
residue was loaded on a silica gel open column and eluted with ethyl 
acetate/hexane (7:3 v/v). The combined and evaporated fractions were crystallized 
from hexane to yield 0.543 g (90%) of pure product IVb. mp 213.0-213.1°C; 
1
H 
NMR (400 MHz, DMSO-d6); 0.89 (t, 3H, J=6.96, J=7.33, CH3), 1.40-1.45 (m, 
2H, CH2CH3), 1.65-1.68 (qt, 2H, CH2CH2CH3), 4.0 (t, 2H, J= 5.86, J=6.23, 
OCH2, 7.16 (d, 1H, J=9.16, Ar-H), 7.39 (d, 1H, J=8.43, Ar-H), 7.55 (s, 1H, Ar-H); 
13
C NMR (400 MHz, DMSO-d6) 14.33, 19.28, 31.31, 69.143, 115.47, 122.96, 
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125.07, 127.45, 130.11, ESI-HRMS (M + H)+ m/z calcd 209.24 
for C11H15NO3; found 210. 
3.2.2. Synthesis of glucocorticoids-H2S donors (FAS I-IV) 
3.2.2.1. Dexamethasone succinate (13). 1.0g (2.55mmol) of dexamethasone 11 
was dissolved in anhydrous pyridine (30mL) and 0.77g (7.65mmol) of succinic 
anhydride and 0.1eq DMAP were then added. After being stirred overnight at 
room temperature, the mixture was evaporated under reduced pressure. The 
resulting residue was then treated with 20 mL of water and the mixture was stirred 
for 20 min and then centrifuged. The obtained precipitate was washed again with 
H2O and filtered. White powder of the product 13 (1.12g) was obtained in a yield 
of 89%. mp 188-189 °C 
3.2.2.2.Dexamethasone-succinate-TBZ (FAS I). To a solution of 13 (1g, 
2.0mmol) in anhydrous tetrahydrofuran (30mL), 4-hydroxythiobenzamide 
(0.613g, 4.0mmol) and DMAP (0.024g, 0.2mmol) were added. The reaction 
mixture was kept on ice bath stirring under nitrogen for 10' and EDC (0.575g, 
3.0mmol) was then added. After the addition, the ice bath was removed and the 
mixture was stirred under nitrogen atmosphere for 3 hour. The solvent was 
evaporated and the residue was purified by column chromatography on silica 
(ethyl acetate: hexane, 6:4). The obtained product FAS I was recrystallized from 
hexane, yielding 0.98g (78 %) of product as a colorless solid. mp 144.5−146.1 
°C
1
H NMR (DMSO-d6) δ 0.78 (d, 3H, J=7.04), 0.88 (s, H), 1.05-1.10 (m, 1H), 
1.48 (s, 3H), 1.53-1.79 (m, 4H),  1.88 (s, 3H), 2.09-2.18 (m, 1H), 2.26-2.40 (m, 
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2H),  2.58-2.61 (m, 3H),  2.79 (t, 2H, J=6.65, J=5.48), 2.82-2.91 (m, 1H), 2.87 (t, 
2H, J=5.87, J=6.26), 5.16 (s, 2H), 5.99 (s, 1H), 6.21 (d, 1H, J=10.17), 7.14 (d, 1H, 
Ar-H, J=8.61), 7.28 (d, 1H, Ar-H, J=10.17), 7.91 (d, 2H, Ar-H, J=8.61),   9.50 (s, 
1H, NH), 9.87 (s, 1H, NH); 
13
C NMR (DMSO-d6)  15.56, 16.70, 23.45, 27.96, 
28.87, 29.36, 30.09, 32.35, 35.86, 36.13, 43.75, 48.21, 48.43, 68.70, 71.30, 90.94, 
100.10, 121.61, 124.54, 127.18, 129.43, 137.52, 153.04, 153.10, 167.81, 170.92, 
171.81, 185.73, 199.48, 205.11.  ESI-HRMS (M + H)
+ 
m/z calcd 627.72 for 
C35H38FNO8S; found 628.0. 
3.2.2.3. Dexamethasone-succinate-ADT (FAS II). The desired product FAS II has 
been obtained following the same procedure above reported for FAS I starting 
from 13 (1g, 2.0mmol) and 5-(p-hydroxyphenyl)-1,2-dithione-3-thione (ADT-
OH) (0.904g, 4.0mmol). ADT-OH was prepared from anethole and sulphur in 
dimethylformamide. Yield: 1.13g (81 %) of product FAS II as a colorless solid. 
mp 134.8−135.1 °C1H NMR (DMSO-d6) δ0.78 (d, 3H, J=7.04), 0.88 (s, H), 1.05-
1.10 (m, 1H), 1.48 (s, 3H), 1.53-1.79 (m, 4H),  1.88 (s, 3H), 2.09-2.18 (m, 1H), 
2.26-2.40 (m, 2H),  2.58-2.61 (m, 3H),  2.80 (t, 2H, J=6.65, J=5.48), 2.82-2.91 (m, 
1H), 2.89 (t, 2H, J=5.87, J=6.26), 5.40 (s, 2H), 5.47 (d, 1H, J=10.17), 5.73 (s, 1H), 
5.96 (s, 1H), 6.21 (d, 1H, J=10.17), 7.14 (d, 2H, Ar-H, J=8.61), 7.80 (s, 1H), 7.95 
(d, 2H, Ar-H, J=8.61); 
13
C NMR (DMSO-d6)  15.57, 16.70, 23.40, 27.72, 28.88, 
29.41, 30.71, 32.35, 34.13, 35.87, 36.12, 43.75, 48.27, 48.44, 68.71, 70.76, 71.12, 
90.94, 123.49, 124.56, 129.12, 129.28, 129.45, 136.26, 153.18, 153.85, 167.50, 
170.85, 171.83, 173.15, 185.72, 205.13. ESI-HRMS (M + H)
+ 
m/z calcd 700.86 
for C35H37FNO8S3; found 700. 
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3.2.2.4. Beclomethasone succinate (14). The desired product 14 has been obtained 
following the same procedure previously reported for compound 13 starting from 
1.0 g (2.45mmol) of beclomethasone 12, 0.73g (7.35mmol) of succinic anhydride 
and 0.1eq DMAP. Yield: 1.15g (14, 92%). mp 180−182.5 °C 
3.2.2.5. Beclomethasone-succinate-TBZ (FAS III).The desired product FAS III 
has been obtained following the same procedure above reported for FAS I starting 
from 14 (1g, 2.0mmol) and 4-hydroxythiobenzamide (0.613g, 4.0mmol). Yield: 
0.87g (67 %) of FAS III as a colorless solid. mp 114.7−115.2 °C1H NMR 
(DMSO-d6) δ 0.92 (s, 3H), 1.01 (d, 3H, J=7.04), 1.05-1.10 (m, 1H), 1.48 (s, 3H), 
1.53-1.79 (m, 4H),  1.88 (s, 3H), 2.09-2.18 (m, 1H), 2.26-2.40 (m, 2H),  2.58-2.61 
(m, 3H),  2.79 (t, 2H, J=6.65, J=5.48), 2.82-2.91 (m, 1H), 2.87 (t, 2H, J=5.87, 
J=6.26), 5.16 (s, 2H), 5.99 (s, 1H), 6.21 (d, 1H, J=10.17), 7.14 (d, 2H, Ar-H, 
J=8.61), 7.28 (d, 1H, J=10.17), 7.91 (d, 2H, Ar-H, J=8.61),  9.50 (s, 1H, NH), 9.87 
(s, 1H, NH); 
13
C NMR (DMSO-d6)  17.66, 20.20, 24.87, 28.04, 28.96, 29.40, 
30.38, 34.50, 35.93, 43.26, 47.32, 49.33, 50.17, 70.02, 74.54, 86.01, 88.32, 
121.64, 124.45, 129.03, 129.17, 137.52, 153.07, 153.24, 167.22, 170.95, 171.79, 
185.69, 199.49, 205.81. ESI-HRMS (M + H)
+ 
m/z calcd 644.17 for C33H38ClO8S; 
found 643.8. 
3.2.2.6. Beclomethasone-succinate-ADT (FAS IV).The desired product FAS IV 
has been obtained following the same procedure above reported for FAS I starting 
from14 (1g, 2.0mmol) and 5-(p-hydroxyphenyl)-1,2-dithione-3-thione (0.904g, 
4.0mmol). Yield: 1.1g (78 %) of FAS IV as a colorless solid.mp 127.7−128.5 
°C
1
H NMR (DMSO-d6) δ0.92 (s, 3H), 1.01 (d, 3H, J=7.04), 1.05-1.10 (m, 1H), 
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1.48 (s, 3H), 1.53-1.79 (m, 4H),  1.88 (s, 3H), 2.09-2.18 (m, 1H), 2.26-2.40 (m, 
2H),  2.58-2.61 (m, 3H),  2.80 (t, 2H, J=6.65, J=5.48), 2.82-2.91 (m, 1H), 2.89 (t, 
2H, J=5.87, J=6.26), 5.40 (s, 2H), 5.47 (d, 1H, J=10.17), 5.73 (s, 1H), 5.96 (s, 
1H),6.21 (d, 1H, J=10.17), 7.14 (d, 2H, Ar-H, J=8.61), 7.80 (s, 1H), 7.95 (d, 2H, 
Ar-H, J=8.61); 
13
C NMR (DMSO-d6)  15.57, 16.70, 23.40, 27.72, 28.88, 29.41, 
30.71, 32.35, 34.13, 35.87, 36.12, 43.75, 48.27, 48.44, 68.71, 70.76, 71.12, 90.94, 
123.49, 124.56, 129.12, 129.28, 129.45, 136.26, 153.18, 153.85, 167.50, 170.85, 
171.83, 173.15, 185.72, 205.13. ESI-HRMS (M + H)
+ 
m/z calcd 717.3 for 
C35H37ClO8S3; found 716.8. 
3.2.3. General procedure for the preparation of 1,2,4-
thiadiazoline-3,5-diones (THIA I-VII) 
A three-necked flask was equipped with a mechanical stirrer and charged with an 
ice-cold solution of corresponding isothiocyanate (1eq) and isocyanate (1eq) in 
anhydrous diethyl ether. Sulfuryl chloride (1eq), dissolved in a minimum volume 
of anhydrous diethyl ether, was added dropwise under inert atmosphere, keeping 
the mixture at 0 °C. After completion of the addition, the solution was stirred at 
room temperature for 48 h. The obtained solid was filtered, dissolved in 10 mL of 
water and vigorously stirred under reflux for 30 minutes. The reaction mixture 
was gradually cooled to 0 °C and the solid was recrystallized from water, filtered 
and dried to yield the pure product as a white solid.  
3.2.3.1. 2,4-diphenyl-1,2,4-thiadiazoline-3,5-dione (THIA I). Compound THIA I 
was prepared from phenyl-isothiocyanate (1g, 7.4mmol) and phenyl-isocyanate 
(0.881g, 7.4mmol) according to a procedure similar to that described above. 
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Yield=74%: mp 119.1−120 °C; 1H NMR (400 MHz, CDCl3)  7.31 (t, 2H, Ar-H, 
J=7.04, J=6.65), 7.46 (t, 4H, Ar-H, J=12.52, J=13.78), 7.55 (d, 2H, Ar-H, J=7.82), 
7.58 (d, 2H, Ar-H, J=7.43);  
13
C NMR (400 MHz, CDCl3)  123.5, 127.2, 127.4, 
129.4, 129.5, 129.6, 132.6, 135.8, 150.4, 164.7; ESI-HRMS (M+H)
+ 
m/z calcd 
270.31 for C14H10N2O2S; found 271.1. 
3.2.3.2. 4-(4-methoxyphenyl)-2-phenyl-1,2,4-thiadiazoline-3,5-dione (THIA II) 
Compound THIA II was prepared from phenyl-isothiocyanate (1g, 7.4mmol) and 
4-methoxyphenyl-isocyanate (0.958mL, 7.4mmol) according to a procedure 
similar to that described above. Yield=72%: mp 155.3−155.4 °C; 1H NMR (400 
MHz, CDCl3) 3.83 (s, 3H, OCH3, J=), 6.95 (d, 2H, Ar-H, J=9.0), 7.43-7.47 (m, 
5H, Ar-H), 7.52 (d, 2H, Ar-H, J=7.43); 
13
C NMR (400 MHz, CDCl3)  55.6, 
114.8, 126.3, 127.3, 128.1, 129.3, 129.4, 132.7, 150.8, 158.9, 165.0; ESI-HRMS 
(M+H)
+ 
m/z calcd 300.33 for C15H12N2O3S; found 301.1. 
3.2.3.3. 4-(4-methoxyphenyl)-2-p-tolyl-1,2,4-thiadiazoline-3,5-dione (THIA III) 
Compound THIA III was prepared from p-tolyl-isothiocyanate (1g, 6.7mmol) 
and 4-methoxyphenyl-isocyanate (0.870mL, 6.7mmol) according to a procedure 
similar to that described above. Yield=74%: mp 156.3−156.5 °C; 1H NMR (400 
MHz, CDCl3)  (s, 3H, -CH33.83 (s, 3H, -OCH36.95 (d, 2H, Ar-H, 
J=9.0), 7.31 (d, 4H, Ar-H, J=6.52), 7.45 (d, 2H, Ar-H, J=9.0); 
13
C NMR (400 
MHz, CDCl3)  21.2, 55.6, 114.8, 126.2, 127.1, 128.2, 130.1, 139.5, 150.9, 158.8; 
ESI-HRMS (M+H)
+ 
m/z calcd 314.36 for C15H12N2O3S; found 315.1. 
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3.2.3.4. 2,4-bis(4-methoxyphenyl)-1,2,4-thiadiazoline-3,5-dione (THIA IV) 
Compound THIA IV was prepared from 4-methoxyphenyl-isothiocyanate (1g, 
6.1mmol) and 4-methoxyphenyl-isocyanate (0.785mL, 6.1mmol) according to a 
procedure similar to that described above. Yield=71%: mp 177.8−177.3 °C; 1H 
NMR (400 MHz, CDCl3) 3.83 (s, 3H, -OCH33.84 (s, 3H, -OCH36.95 (d, 
2H, Ar-H, J=7.04), 7.01 (d, 2H, Ar-H, J=7.43), 7.34 (d, 2H, Ar-H, J=6.65), 7.45 
(d, 2H, Ar-H, J=7.05); 
13
C NMR (400 MHz, CDCl3)  55.5, 55.6, 114.7, 114.8, 
125.3, 126.2, 128.2, 128.6, 151.0, 158.8, 160.0, 165.2; ESI-HRMS (M+H)
+ 
m/z 
calcd 330.36 for C16H14N2O4S; found 331.1. 
3.2.3.5. 2-(4-chlorophenyl)-4-(4-methoxyphenyl)-1,2,4-thiadiazoline-3,5-dione 
(THIA V) Compound THIA V was prepared from 4-chlorophenyl-isothiocyanate 
(1g, 5.9mmol) and 4-methoxyphenyl-isocyanate (0.764mL, 5.9mmol) according 
to a procedure similar to that described above. Yield=76%: mp 182.7−183.4 °C; 
1
H NMR (400 MHz, CDCl3)  3.83 (s, 3H, OCH3), 6.95 (d, 2H, Ar-H, J=8.61), 
7.40 (d, 2H, Ar-H, J=8.61), 7.44 (d, 2H, Ar-H, J=7.04), 7.49 (d, 2H, Ar-H, 
J=8.61); 
13
C NMR (400 MHz, CDCl3)  55.6, 114.8, 126.4, 127.8, 128.6, 129.6, 
131.1, 135.2, 150.5, 159.0, 164.8; ESI-HRMS (M+H)
+ 
m/z calcd 334.78 for 
C15H11ClN2O3S; found 335.8. 
3.2.3.6. 2-cyclohexyl-4-(4-methoxyphenyl)-1,2,4-thiadiazoline-3,5-dione (THIA 
VI) Compound THIA VI was prepared from cyclohexyl-isothiocyanate (1g, 
7.1mmol) and 4-methoxyphenyl-isocyanate (0.917mL, 7.1mmol) according to a 
procedure similar to that described above. Yield=77%: mp 98.8−99.7 °C; 1H 
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NMR (400 MHz, CDCl3)  1.18-1.41 (m, 6H, cyclohexane: (CH2)3), 1.78-1.89 (q, 
2H, cyclohexane: CH2), 2.25-2.31 (q, 2H, cyclohexane: CH2), 3.81 (s, 3H, OCH3), 
4.18-4.23 (qt, 1H, cyclohexane-CH), 6.92 (d, 2H, Ar-H, J=11.7), 7.37 (d, 2H, Ar-
H, J=8.7);
13
CNMR(400MHz,CDCl3)25.2, 26.1, 29.1, 55.0, 55.6, 118.9, 129.5, 
132.4, 150.5, 159.0, 164.7; ESI-HRMS (M+H)
+ 
m/z calcd 306.38 for 
C15H18N2O3S; found 307.1. 
3.2.3.7. 2-benzyl-4-(4-methoxyphenyl)-1,2,4-thiadiazoline-3,5-dione (THIA VII) 
Compound THIA VII was prepared from benzyl-isothiocyanate (1g, 6.7mmol) 
and 4-methoxyphenyl-isocyanate (0.868mL, 6.7mmol) according to a procedure 
similar to that described above. Yield=75%: mp 113.7−114.5 °C; 1H NMR (400 
MHz, CDCl3)  3.81 (s, 3H, OCH3), 4.90 (s, 2H, N-CH2), 6.92 (d, 2H, OCH3, 
J=8.60), 7.24-7.39 (m, 5H, Ar-H); 
13
C NMR (400 MHz, CDCl3)  46.2, 55.6, 
114.7, 126.2, 128.1, 128.4, 128.8, 129.1, 135.1, 151.4, 158.8, 165.4; ESI-HRMS 
(M+H)
+ 
m/z calcd 314.36 for C16H14N2O3S; found 315.0. 
3.3. Pharmacology 
3.3.1. Cysteine surrogates: propargylamide and n-butylamide 
derivatives 
3.3.1.1. Isolated rat aortic ring assay 
CD-1 mice were sacrificed and thoracic aorta was rapidly dissected and 
cleaned from fat and connective tissue. For endothelium-denuded rings, the 
endothelial layer was removed by gently rubbing the internal surface of the 
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vascular lumen. Rings of 1.5–2 mm length were cut and mounted in isolated organ 
baths filled with gassed Krebs solution (95% O2 + 5% CO2) at 37 °C linked to 
isometric force transducers (Ugo Basile, Comerio, Varese, Italy). The composition 
of the Krebs solution was as follows (mol/l): NaCl 0.118, KCl 0.0047, MgSO4 
0.0023, KH2PO4 0.0012, CaCl2 0.0025, NaHCO3 0.025 and Glucose 0.010. Rings 
were initially stretched until a resting tension of 1.5 g was reached and allowed to 
equilibrate for at least 45 min during which tension was adjusted, when necessary, 
to 1.5 g and bathing solution was periodically changed. In a preliminary study a 
resting tension of 1.5 g was found to develop the optimal tension to stimulation 
with contracting agents. 
In each experiment, rings were firstly contracted with L-phenylephrine 
(PE) 3 μmol/l and subsequently with L-phenylephrine (PE) 1 μmol/l until the 
response were reproducible. To verify the integrity of the endothelium, Ach 
cumulative concentration-response curve (10nM – 30µM) was performed on PE-
contracted rings.   
Aortic rings were contracted with PE (1µM), once plateau was reached, a 
cumulative concentration-response curve to surrogate cysteine or derived 
compounds (10nM – 300µM) was performed. 
In another set of experiments aortic rings were incubated with the cysteine 
surrogates or with their derivatives at different concentration (1mM or 100µM) 
for 30 minutes. After that time, rings were contracted with PE (1µM), once 
reached a plateau, a cumulative concentration-response curve to L-cysteine (1µM-
3 mM) was performed. 
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All data are presented as means ± SEM. Statistical analysis was performed 
by one-way ANOVA followed by Newman–Keuls multiple comparison test. 
Differences were considered statistically significant when P-value was less than 
0.05. GraphPadPrism software (GraphPad Software, Inc., La Jolla, CA, USA)was 
used for all the statistical analysis. 
3.3.1.2. Measurement of H2S production: methylene blue assay 
H2S determination was performed according to Stipanuk and Beck 
(Stipanuk and Beck, 1982) with modifications.  
Briefly, thoracic aorta was dissected, placed in sterile phosphate buffer 
solution and cleaned of fat and connective tissue. The aortic rings were 
homogenized in a lysis buffer (potassium phosphate buffer 100 mM pH=7.4, 
sodium orthovanadate 10 mM and protease inhibitor) and the protein 
concentration was determined using Bradford assay (Bio-Rad Laboratories, 
Milano, Italy). The homogenates were treated with cysteine surrogates and their 
derived compounds at different concentration for 30 minutes and then added in a 
reaction mixture (total volume 500µl) containing piridoxal-5’-phosphate (2mM, 
20µl), L-cysteine (10mM, 20µl) and saline (30µl). The reaction was performed in 
parafilmed eppendorf tubes and initiated by transferring tubes from ice to a water 
bath at 37°C. After incubation of 30 minutes, ZnAc (1%, 250µl) was added to trap 
evolved H2S followed by TCA (10%, 250µl). Subsequently, N,N-dimethyl-p-
phenylenediamine-sulfate (20µM, 133µl) in 7.2M HCl and FeCl3 (30µM, 133µl) 
in 1.2M HCl were added. After 20 minutes absorbance values were measured at a 
wavelength of 650 nm. All samples were assayed in duplicate and H2S 
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concentration was calculated against a calibration curve of NaHS (3.12-250µM). 
Results were expressed as nmoles per milligram of protein. 
3.3.2. Glucocorticoids-H2S donors 
3.3.2.1. Cell cultures and Nitrite determination 
The murine monocyte/macrophage J774 cell line was grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 2 mM glutamine, 25 mM 
hepes, penicillin (100 units/mL), streptomycin (100 g/mL), 10% fetal bovine 
serum (FBS), and 1.2%sodium pyruvate. 
Cells were plated to a seeding density of either 2 x 10
6
 in P60 well plates or 
2.5 x 10
5
 in 24 multiwell plates. Cells were pretreated (for 2h) with increasing 
concentration of the tested compounds and stimulated with LPS from Escherichia 
coli, serotype 0111:B4 (10 g/mL). Treatment with tested compounds and/or LPS 
was carried out under serum-free conditions. The concentrations of the FAS 
utilized (0.1 and 1 g/mL) were chosen according to what was reported in the 
literature. 
Cells were pretreated with tested compounds for 2 hand further incubated 
for 24 h with LPS (10 g/mL). At the end of the incubation, the supernatants were 
collected for the nitrite measurement. 
The nitrite concentration in the samples was measured by the Griess 
reaction, by adding 100 L of Griess reagent (0.1% N-(1-
naphthyl)ethylenediamide dihydrochloride in H2O and 1% sulfanilamide in 5% 
H3PO4; vol. 1:1) to 100 L samples. The optical density at 550nm (OD550) was 
measured using an ELISA microplate reader (SLT Lab instruments, Salzburg, 
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Austria). Nitrite concentration was calculated by comparison with OD550 of 
standard solutions of sodium nitrite prepared in culture medium. 
3.3.3. 1,2,4-Thiadiazolidine-3,5-diones 
3.3.3.1. Amperometric determination of H2S  
The characterization of the potential H2S-generating properties of the tested 
compounds has been carried out by an amperometric approach, using the Apollo-
4000 free radical analyzer (WPI) detector and H2S-selective mini-electrodes.  
The experiments have been carried out at room temperature. The H2S-
selective mini-electrode was equilibrated in 10 mL of the assay buffer 
(NaH2PO4·H2O 1.28 g, Na2HPO4·12H2O 5.97 g, NaCl 43.88 g in 500 mL H2O), 
until the recovery of a stable baseline. Then, 100 μL of a DMSO solution of all the 
tested THIAs was added (the final concentration of the tested compounds was 1 
mM; the final concentration of DMSO in the AB was 1%). 
The selected compounds were tested in absence and in presence of L-
cysteine and when required by the experimental protocol, L-cysteine (4 mM) was 
added before the addition of the THIAs. The H2S generation was monitored for 20 
min. H2S concentration was determined against a calibration curve obtained 
plotting amperometric currents (recorded in pA) vs. increasing concentrations of 
NaHS (1, 3, 5, and 10 µmol/L) at pH 4.0. 
3.3.3.2. Isolated rat aortic ring assay 
CD-1 mice were sacrificed and thoracic aorta was rapidly dissected and 
cleaned from fat and connective tissue. For endothelium-denuded rings, the 
endothelial layer was removed by gently rubbing the internal surface of the 
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vascular lumen. Rings of 1.5–2 mm length were cut and mounted in isolated organ 
baths filled with gassed Krebs solution (95% O2 + 5% CO2) at 37 °C linked to 
isometric force transducers (Ugo Basile, Comerio, Varese, Italy). The composition 
of the Krebs solution was as follows (mol/l): NaCl 0.118, KCl 0.0047, MgSO4 
0.0023, KH2PO4 0.0012, CaCl2 0.0025, NaHCO3 0.025 and Glucose 0.010. Rings 
were initially stretched until a resting tension of 1.5 g was reached and allowed to 
equilibrate for at least 45 min during which tension was adjusted, when necessary, 
to 1.5 g and bathing solution was periodically changed. In a preliminary study a 
resting tension of 1.5 g was found to develop the optimal tension to stimulation 
with contracting agents. 
In each experiment, rings were firstly contracts with L-phenylephrine (PE) 3 
μmol/l and subsequently with L-phenylephrine (PE) 1 μmol/l until the response 
were reproducible. To verify the integrity of the endothelium, Ach cumulative 
concentration-response curve (10nM – 30µM) was performed on PE-contracted 
rings.   
Aortic rings were contracted with PE (1µM), once plateau was reached, a 
cumulative concentration-response curve to THIA (10nM – 300µM) was 
performed. In another set of experiments, rings were denuded of the endothelium 
and THIA cumulative concentration-response curve was performed (10nM – 
300µM). 
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4. Results and Discussion 
4.1. Cysteine surrogates: propargylamide and n-butylamide 
derivatives 
In order to evaluate the inhibitory activity of the selected compounds, we 
firstly tested the commercially available cysteine surrogates on the L-cysteine-
induced vasorelaxation in rat aortic rings and compared the results to the effect 
obtained with synthesized compounds. In physiological conditions, L-cysteine 
induced vasorelaxation, in a concentration-dependent manner, with a maximum 
value of 39,8 ± 5%. 
The pre-treatment with the compound II reduced the L-cysteine-induced 
vasorelaxation in a concentration-dependent manner. Indeed, the tested compound 
at the concentration of 1 mM reduced the vasorelaxation significantly and at the 
concentration of 3 mM achieved the Emax value of 13.7 ± 6.1% 
(n=3;***=p<0,001). In contrast, the treatment with the compound II (Figure 11) 
tested at the concentration of 100 M did not affect the L-cysteine-induced 
vasorelaxation (Emax 27,7±11,1% II vs 39,8±5% vehicle respectively; n=3). 
Figure 12 shows the results obtained with the compound III. In particular, 
this compound, tested at the concentration of 10 mM, significantly reduced the L-
cysteine-induced vasorelaxation, (Emax 26±5%  III vs 39,8±5% vehicle; n=4). 
This effect was concentration-dependent, in fact, the pre-treatment with the 
compound III at the concentration of 1 M, did not affect the L-cysteine-induced 
vasorelaxation (Emax 26 ± 5% III vs 39.8 ± 5 % vehicle; n = 4). 
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In contrast, as shown in figure 10, the pre-treatment with the compound I 
induced a significant increase of the L-cysteine induced vasorelaxation effect 
(Emax 74.0 ± 17.6% I vs 39.8 ± 5% vehicle; n = 4; *** = p <0.001). 
Incubation of aortic rings with the compound IIa at the concentration of 100 
M (Figure 14) completely abrogated the L-cysteine-induced vasorelaxation, 
achieving the Emax value of 13.7 ± 6.1%(n=3;***=p<0,001), but unaffected by Ia 
(Figure 13). 
A similar pattern of inhibition was obtained with the compound IIIa 
(Figure 15). In particular L-cysteine-induced vasorelaxation was reduced by pre-
treatment with the compound IIIa. However, compared to IIa, the compound 
IIIa, even at the highest concentration tested (1mM), was not able to completely 
abrogate the relaxation (Emax 13,3±1,8% IIIa 1mM; 24,0±2,0 IIIa 100 μM, vs 
39,8±5% vs vehicle; n=3; * p< 0,05; ** p< 0,01). 
Furthermore, the synthesized compounds were also tested for their potential 
as vasorelaxing agents on rat aortic rings and these relaxations were compared to 
those obtained in the presence of L-cysteine (Figure 16).Compounds Ia and IIa 
have also showed a vasorelaxing ability that was similar or slightly higher than 
the L-cysteine (Emax 51,3±14,8% IIa; 49±10,0%IIIa; 31±16,1% vs 38,8±9,5%Ia 
vs L-cys; n=3). 
In another set of experiments, n-butylamide derivatives (Ib-IIIb) were 
tested for their ability to inhibit the L-Cys induced vasorelaxation on rat aortic 
rings pre-contracted with PE but none of tested compounds affected the 
vasorelaxation effect (data not shown). 
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With regard to parsalmide (IV) and its derivatives (IVa and IVb), all of 
them significantly inhibited L-cysteine induced vasorelaxation (Figure 17) and IV 
and IVb also showed vasorelaxant activities (Figure 18).  
Additionally, in order to evaluate a possible involvement of L-Cys/H2S 
pathway, the compounds showing the higher inhibitory action, were tested by 
measuring H2S production and the methylene blue assay was performed. 
Under basal conditions, tissue homogenates produced 1,4 ± 0,08 % nmol of 
H2S per mg of protein and the addition of exogenous L-Cys boosted the 
production of H2S by 2-fold. 
Incubation with compounds II, III, IIa and IIIa significantly inhibited the 
increase in H2S production stimulated with L-Cys. These results confirmed those 
obtained from ex vivo experiments. In fact, as shown in figure 20, pre-treatment 
with the propargylamide derivative compounds (IIa, 100 M and IIIa, 1mM) 
reduced H2S production compared to the vehicle (Emax 2,7±0,09 nmol/mg).  
Comparing the compounds IIa (Emax 2,1±0,07% nmol/mg protein
*min-1
 
(n=4)) and IIIa (Emax 1,960±0,06% nmol/mg protein
*min-1
(n=3)), they showed a 
comparable inhibitory action on H2S production, but the effect of the compound 
IIa was obtained with a lower dose (Ia, 100 M vs IIIa, 1mM). 
On the basis of the obtained results, we decided to compare the inhibitory 
activity of the compound IIa with the known CSE inhibitor, D,L-propargylglycine 
(PGG) (Figure 19).  
Incubation of aortic rings with the compound IIa completely abrogated the 
L-cysteine-induced vasorelaxation, achieving the Emaxvalue of 
3,7±0.88%(n=3;***=p<0,001), while PGG reduced but not completely abrogated 
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the L-cysteine-induced vasorelaxation (Emax  20,3±5.2%nmol/mg protein
*min-
1
(n=3) vs 45,3±6.7% nmol/mg protein
*min-1 
vehicle), despite it was tested at an 
higher concentration (1mM vs 100M; PGG vs IIa). 
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Figure 10- Effect of compound I on L-cysteine-induced vasorelaxation. 
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Figure 11- Effect of compound II on L-cysteine-induced vasorelaxation. 
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Figure 12- Effect of compound III on L-cysteine-induced vasorelaxation. 
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Figure 13- Effect of compound Ia on L-cysteine-induced vasorelaxation. 
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Figure 14- Effect of compound IIa on L-cysteine-induced vasorelaxation. 
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Figure 15- Effect of compound IIIa on L-cysteine-induced vasorelaxation. 
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Figure 16- Effect of propargylamide derivatives (Ia-IIIa), compared to L-
cysteine, on vasorelaxation. 
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Figure 17- Effect of parsalmide (IV) and derivatives (IVa-IVb) on L-cysteine-
induced vasorelaxation. 
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Figure 18- Effect of propargylamide derivatives (Ia-IIIa), compared to L-
cysteine on vasorelaxation. 
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Figure 19- Effect of compound IIa, compared to the CSE inhibitor PGG on L-
cysteine-induced vasorelaxation. 
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Figure 20- Measurement of H2S production in rat aortic rings homogenates with 
II, III, IIa and IIIa compounds, compared to PGG. 
4.2. Glucocorticoids-H2S donors 
Asthma is one of the most common chronic inflammatory disorder of the 
airways of the lungs. Nitric oxide (NO) is endogenously produced in mammalian 
airways by nitric oxide synthase (NOS) and is known to regulate many aspects of 
human asthma, including the modulation of airway and vascular smooth muscle 
tone and the inflammation. Asthmatic patients show an increased expression of 
inducible nitric oxide synthase (iNOS) in airway epithelial cells and an increased 
level of NO in exhaled air. iNOS produces large amounts of NO (Alderton et al., 
2001), in response to inflammatory signals, such as cytokines and 
lipopolysaccharides (LPS). 
The glucocorticoids have been reported to inhibit iNOS induction, which 
may contribute to the inflammation-reducing effects. Specifically, glucocorticoids 
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(10-250 nM) inhibited the expression of iNOS mRNA and protein dose and time 
dependently, resulting in decreases in NO production. 
On the other hand, a growing number of observations suggest that, similarly 
to NO, hydrogen sulfide might be of biological relevance as an endogenous 
gasotransmitter in the pathogenesis of airway diseases, such as COPD and asthma 
(Chen and Wang, 2012). Endogenous H2S may exert its anti-inflammatory effect 
by inhibiting inducible nitric oxide synthase (iNOS)/NO pathway. Cystathionine-
γ-lyase is mainly expressed in airway and vascular smooth muscle cells in rat lung 
tissue.  
For these reasons, we tested the synthetized hybrids on J774 macrophages 
stimulated with LPS (10 g/mL), measuring the NO production and comparing 
obtained data to the pure glucocorticoids (dexamethasone and beclomethasone 
succinates).  
In J774 cells stimulated with LPS, pure glucocorticoids clearly inhibited NO 
formation in a concentration-dependent manner, as shown in Figure 21and 22, 
comparing two sets of data at different concentration (log M -7 vs. log M -6).  
When succinate glucocorticoids and derivatives were given to cells 2 h 
before LPS, the inhibitory activity of dexamethasone succinate was lower than its 
derivatives, glucocorticoid-H2S donors (FAS I and II), but this effect did not 
occur with beclomethasone derivatives. Specifically, pretreatment with FAS III 
and IV 2 h before LPS did not induce any inhibition (Figure 21). 
These data suggested that a pre-incubation of 2 h was not enough to lead to 
the hydrolysis of ester bond in beclomethasone-hybrids, allowing the release of 
the pure glucocorticoid and its H2S donor moieties. 
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Consequently, another set of experiments was performed and J774 cells 
were pretreated for a longer time (4h). The obtained data confirmed the enhanced 
inhibitory activities of dexamethasone-H2S donors (FAS I and II), compared to 
the precursor, dexamethasone succinate (Figure 22).  
These results supported our hypothesis that the anti-inflammatory effect 
could be enhanced with hybrids containing glucocorticoids and H2S releasing 
moiety, both responsible for inhibitory action on inducible nitric oxide synthase.  
In contrast, the effect of beclomethasone succinate on nitrite production, 
even at the highest concentration used (1M), resulted equal or greater than that 
obtained with its derivatives (FAS IV and III, respectively). 
This result can be explained by the presence of a chlorine atom into the 9-
position of a pregnane steroid, instead of fluorine, that could have a long range 
effect on ester bond, slowing down the hydrolysis and the subsequent hydrogen 
sulfide release. 
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Figure 21 - Effect of glucocorticoids and derivatives on nitrite production. J774 
macrophages were pretreated for 2 h with glucocorticoids and derivatives. 
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Figure 22 - Effect of glucocorticoids and derivatives on nitrite production. J774 
macrophages were pretreated for 4 h with glucocorticoids and derivatives. 
4.3. 1,2,4-Thiadiazolidine-3,5-diones 
In order to characterize the potential H2S-releasing properties of 1,2,4-
thiadiazolidine-3,5-diones, all compounds were added at 1 mM concentration to 
the assay buffer. The generation of H2S was evaluated by an amperometric 
approach, allowing to have a real-time determination of the H2S-release and thus 
to perform a qualitative/quantitative description of the process. 
The experiments were also performed in the presence of 4 mM L-cysteine. 
The incubation of THIA I-VII  in the assay buffer led to a negligible release of 
H2S (data not shown); in contrast, in the presence of L-cysteine, all compounds 
(VII except) exhibited a slow and significant release of H2S (Figure 23). 
Noteworthy, the previous amperometric measurements indicated that THIAs 
ensured a long-lasting release of H2S, requiring the presence of L-cysteine.  
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Figure 23 - Amperometric determination of H2S. Hydrogen sulfide-release 
from THIAs in the presence of L-cysteine. The curves describe the increase of the 
H2S concentration with respect to time, following the incubation of THIA I-VII in 
the presence of L-cysteine. 
Additionally, to prove the nature of 1,2,4 thiadiazolidine 3,5 diones as 
spontaneously releasing H2S donors, further pharmacological experiments were 
performed. In these studies, the endothelium-intact or endothelium-denuded aortic 
rings were exposed to the THIA I-VII. 
The tested compounds induced a vasorelaxant effect, irrespective of whether 
endothelium was present or not.  In particular, incubation of aortic rings with 
THIA I (Figure 24), II (Figure 25), III (Figure 26), V (Figure 28) and VI 
(Figure 29) allowed us to obtain the maximum vasorelaxant effect, that was 
independent of endothelium. 
Furthermore, the pre-treatment of endothelium-intact aortic rings with 
THIA IV induced a maximum vasorelaxation, as well as the other compounds of 
the series, but the response was reduced in endothelium-denuded rings (75%) 
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(Figure 27). Instead, the removal of the endothelium showed an increase of the 
vasorelaxing capacity of THIA VII (Figure 30).  The obtained results suggested 
that the presence of endothelium with all their components could affect the release 
of the hydrogen sulfide. 
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Figure 24 – Effect of THIA I compound on endothelium-denuded and 
endothelium-intact aortic rings. 
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Figure 25 – Effect of THIA II compound on endothelium-denuded and 
endothelium-intact aortic rings. 
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Figure 26 – Effect of THIA III compound on endothelium-denuded and 
endothelium-intact aortic rings. 
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Figure 27 – Effect of THIA IV compound on endothelium-denuded and 
endothelium-intact aortic rings. 
-8 -7 -6 -5 -4 -3
0
25
50
75
100
vehicle (dmso)
+ endothelium
***
- endothelium
 THIA V (log M)
%
 r
e
la
x
a
ti
o
n
Figure 28 – Effect of THIA V compound on endothelium-denuded and 
endothelium-intact aortic rings. 
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Figure 29 – Effect of THIA VI compound on endothelium-denuded and 
endothelium-intact aortic rings. 
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Figure 30 – Effect of THIA VII compound on endothelium-denuded and 
endothelium-intact aortic rings. 
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5.  NMR-based metabolomics 
5.1. Objectives 
In order to confirm the promising results obtained in ex vivo tissues with the 
synthesized compound IIa, able to completely inhibit L-cysteine-induced 
vasorelaxation, the effects of the selected compound were further tested on the 
purified recombinant enzymes.  
For this purpose, a metabolomic approach based on nuclear magnetic 
resonance techniques was used, upon expression, purification and characterization 
of CBS and CSE enzymes. 
5.2. Expression and purification of recombinant CBS and CSE 
enzymes.  
5.2.1. Plasmids, bacterial strains and media 
E. coli BL21 (DE3) Codon Plus was used as the host strain to express 
recombinant human CSE or CBS. CSE cDNA was cloned into pGEX-4T3 and 
CBS into pGEX-Kg to create N-terminal GSH-S-transferase (GST) fusion 
proteins. The expression vectors were transformed and plated on LB-agar plates, 
supplemented with ampicillin (100 mg·mL
-1
). 
5.2.2. Bacterial expression of human CBS enzyme 
The expression and purification of CBS was performed as described 
previously with modifications (Huang, 2010). 
A colony of the pGEX-Kg/GST-CBS transformed BL21 cells was 
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inoculated into 100 mL of steam-autoclaved Luria-Bertani (LB) broth 
supplemented with 100 μg/mL of ampicillin (LB-Amp100), and incubated at 37 
°C overnight with vigorous shaking. 
A part of starter culture (40 mL) was propagated into 5 L buffled flask, 
containing 960 mL of LB-Amp100. The mixture was incubated at 37 °C with 
vigorous shaking until an optical density of 0.3 at 600 nm (OD600) was attained, 
upon which bacterial growth was continued at 30 °C until an OD600 of 0.5 was 
attained. 
 After the addition of 0.3 mM -ALA, IPTG was added at a rate of 0.1 mM 
to induce the expression of human CBS at 30 °C for 18 h. The cells were 
harvested by centrifugation in a Beckman Avanti centrifuge J-26XP equipped with 
a JSP-FIBERLite rotor at 5000 rpm  for 40 min at 4 °C.  The supernatants were 
thrown away and the pellets, re-suspended in PBS (140 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3), were kept at -20 °C overnight. 
5.2.3. Bacterial expression of human CSE enzyme 
The expression and purification of CSE was adapted from a previously 
described (Huang, 2010). 
A colony of the pGEX-4T-3/GST-CSE transformed BL21 cells was 
inoculated into 100 mL of steam-autoclaved Luria-Bertani (LB) broth 
supplemented with 100 μg/mL of ampicillin (LB-Amp100), and incubated at 37 
°C overnight with vigorous shaking.  
A part of starter culture (40 mL) was propagated into 5 L buffled flask, 
containing 960 mL of LB- Amp100. The mixture was incubated at 37 °C with 
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vigorous shaking until an optical density of 0.3 at 600 nm (OD600) was attained,  
upon which bacterial growth was continued at 18 °C until an OD600 of 0.5 
was attained. IPTG was then added at a rate of 0.1 mM to induce the expression of 
human CSE at 18 °C for 18 h. The cells were harvested by centrifugation in a 
Beckman Avanti centrifuge J-26XP equipped with a JSP-FIBERLite rotor at 5000 
rpm  for 40 min at 4 °C.   
The supernatants were thrown away and the pellets, re-suspended in PBS 
(140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3), were 
kept at -20 °C overnight. 
5.2.4. Purification of human enzymes 
The bacterial pellets were thawed and re-suspended in lysis buffer 
containing PBS pH 7.3, 1% Igepal, 5 mM dithiothreitol (DTT), 100 mM PLP, 
protease inhibitors (Complete EDTA-free tablet), DNAse I and Lysozyme. Cell 
lysis was performed by sonication on ice using the 30% pulsed maximum output 
of a Brandson Sonifier 250 equipped with a macrotip. The lysates were then 
cleared by centrifuging at 16000 rpm for 30 min at 4 °C using a Beckman JA20 
rotor.  
The soluble fractions, containing the GST-CBS and GST-CSE recombinant 
proteins respectively, were loaded onto a Glutathione sepharose 4B columns 
previously equilibrated with binding buffer PBS. The columns were sealed and 
incubated with slight shaking in a cold room (4 °C) for 20 min. 
Following that, the flow-throughs were collected, and the beads were 
washed with five column volumes of binding buffer. Proteins attached to the 
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columns were eluted with five column volumes of elution buffer (50 mM Tris–
HCl, 10 mM reduced GSH, 5mM DTT,  pH 8.0) and then dialyzed and 
concentrated in 10 mM sodium phosphate buffer pH 8.2 and DTT 1 mM. 
This was repeated until minimal protein concentration was detected in the 
eluates by Bradford assay. The eluates were then pooled together and concentrated 
using an ultra-centrifugal filter (Millipore Amicon Ultra-4 30000 MWCO) at 4 °C.  
The concentrated eluates were subsequently passed through a  Superdex-200 
column connected to the AKTA purifier FPLC equilibrated with buffer A (10 mM 
sodium phosphate buffer pH 8.2 and 1 mM DTT) at a flow rate of 1 mL/min 
(Figure 31). 
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Figure 31 - FPLC chromatography.Gel filtration profile of GST-CBS (A) and 
GST-CSE (B) proteins. 
Fractions containing CBS and CSE respectively were identified by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and then pooled 
together. Peak fractions corresponding to the target CBS and CSE proteins were 
pooled together and concentrated to about 5 mg/mL in 10 mM sodium phosphate 
buffer pH 8.2 and 1 mM DTT using an ultra-centrifugal filter (Millipore Amicon 
Ultra-4 10000 MWCO) at 4 °C. The proteins were kept at -80 °C for long-term 
storage. 
The purity of the recombinant enzymes was checked by SDS-PAGE on 12% 
polyacrylamide gels after staining of protein bands with Coomassie dye (Figure 
32). 
GST was not removed from the fusion proteins as it has been previously 
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reported that the presence of GST does not affect activity. Furthermore, GST did 
not interfere with the assay, since no H2S-synthesizing activity was observed in a 
control activity experiment with GST alone (Huang, 2010). 
 
 
 
 
Figure 32 - Representative SDS-PAGE. Fractions after different purification 
steps of recombinant GST-CBS (a) and GST-CSE (b) from bacterial cell lysates. 
Lanes: M, protein marker; 1, cell Lysate before purification; 2. flow through; 3. 
wash with binding buffer; 4. eluted GST-CBS or GST-CSE; 5. purified proteins 
after gel filtration. 
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5.3. Structural characterization of recombinant enzymes 
5.3.1. Analysis of protein secondary structure via circular 
dichroism (CD) measurements 
Far-UV CD measurements were performed on a J-715 spectropolarimeter 
(JASCO, Oklahoma City, OK) equipped with a PTC-348 Peltier temperature 
control system. The instrument was flushed with nitrogen gas, after which the 
nitrogen gas flow was maintained at a flow rate of 4 L/min. Samples were 
prepared using an enzyme concentration of 4 µM in 10 mM sodium phosphate pH 
8.2 buffer. The spectra were recorded at different time points using quartz cuvettes 
(Hellma, Plainview, NY) with path-lengths of 1 mm.  
Baseline correction was performed by subtraction of the appropriate buffer 
spectrum. The recorded CD spectra resulted from averaging five separate 
wavelength scans on independent protein preparations to ensure reproducibility of 
the results. The parameters were scanned wavelength from 260 nm to 190 nm, 
scanning speed 200 nm/min, data pitch 0.2 nm, 2 nm slit width, temperature 37 °C 
for each protein (Figure 33).  
CD intensities are presented as the CD absorption coefficient calculated 
using the molar concentration of the proteins (ΔεM). Far-UV CD spectral 
decomposition to obtain the secondary structure content was achieved with the 
CONTIN, SELCON, and CDSSTR methods (Figure 34).  
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Figure 33 - Circular dichroism. Far-UV CD spectra of GST-CBS (A) and GST-
CSE (B) in 10 mM sodium phosphate pH 8.2  
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Figure 34 - Circular dichroism, the secondary structure content. Proportion of 
α-helices, β-sheets, turns and unordered regions of GST-CBS (A) and GST-CSE 
(B) achieved with the CONTIN, SELCON, and CDSSTR methods. 
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5.3.2. UV-vis Spectroscopy Analysis of recombinant enzymes CBS 
and CSE 
Adsorbance spectroscopy was carried out on a Varian Cary 50 Bio UV-
Visible Spectrophotometer. The analyzed samples were dissolved in 10 mM 
sodium phosphate pH 8.2.  
Measurements were performed in a 1 cm cuvette cell and monitored 
spectroscopically from 650nm to 250 nm. The absorption spectrum of human 
CBS exhibited a peak at 430 nm (Figure 35A) suggesting the presence of haem in 
the recombinant protein. As shown in Figure 35B, the purified CSE enzyme 
displayed the characteristic 427 nm absorbance peak which corresponded to the 
Schiff-base linkage between PLP and Lys-212. 
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         B. 
 
Figure 35 - Absorption spectroscopy. UV-vis absorption spectra of purified CBS 
(A) and CSE (B) enzymes in 10 mM phosphate buffer pH = 8.2. 
 
 
5.3.3. Kinetics of H2S production from purified recombinant 
human CBS and CSE 
5.3.3.1. Determination of H2S standard curve 
A mixture of 0.85 % w/v ZnAc and 3 % w/v NaOH (100 μL) was 
added to various H2S standards (0-60 μM, 100 μL) prepared in 50 mM 
sodium phosphate pH 8.2 buffer containing 0.5 mM PLP, 20 mM 
NaCl and 0.1 mM DTT. TCA (10 % w/v, 100 μL) was added and the 
tubes were then treated with NNDPD (20 mM, 42.9 μL) and FeCl3 (30 
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mM, 42.9 μL). After a short spin, 300 μL of the supernatant was 
removed for absorbance measurements at 670 nm. 
The calibration curve was generated by plotting the average A670 
value against the amount of H2S present for each standard (Figure 
36). 
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Figure 36 - H2S standard curve. A. UV-vis spectra of H2S standards using the 
methylene blue assay.  B. Calibration curve of the spectrophotometric detection of 
hydrogen sulfide.  
5.3.3.2. Enzyme activities 
In order to verify the catalytic activities of the purified enzymes, hydrogen 
sulfide production was measured by the methylene blue method. The assay was 
performed according to Stipanuk and Beck (1982) with some modifications.  
Each reaction mixture consisted of 5 μg of the purified enzyme, saline (10 
μL), and L-cysteine (27.5 mM, 10 μL), dissolved in 10mM sodium phosphate pH 
8.2 buffer to a final volume of 100 μL. For the CBS enzyme, the reaction mixture 
contained the same as for the CSE plus 27.5 mM homocysteine (10 μL). 
The Eppendorf tubes were parafilmed tightly, gently vortexed, and then 
incubated in a 37 °C water bath. After 60 min of incubation, the evolved H2S was 
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trapped via addition of ZnAc (1 % w/v, 100 μL) and proteins were precipitated via 
addition of TCA (10 % w/v, 100 μL).  
 
 
Figure 37 - Reaction of methylene blue assay 
Subsequently, N,N-dimethyl-p-phenylenediamine-sulfate in 7.2 M HCl was 
immediately followed by addition of FeCl3 in 1.2 M HCl, for development of 
methylene blue,  according to the reaction equation shown above (Figure 37). 
The amount of H2S produced was then determined via absorbance 
measurements of the centrifugal supernatants. The absorbance of the resulting 
solution was measured at 655 nm (Figure 38). 
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Figure 38 - Spectrophotometric method using methylene blue assay. 
Measurement of H2S producing CBS (A) and CSE enzymes (B). 
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5.4.   Enzyme Kinetics: NMR spectroscopy 
Metabolomics Nuclear Magnetic Resonance technique was used to study the 
kinetics of two main enzymes involved in trans-sulfuration pathway. Specifically, 
CBS converts L-cysteine and L-Homocysteine into L-cystathionine (Figure 39A) 
and CSE enzyme utilizes L-cysteine as a substrate in an α,β-elimination reaction 
to produce H2S, pyruvate and ammonia (Figure 39B). NMR spectra were 
acquired to follow the disappearance of the L-Cysteine peaks over time, 
monitoring its conversion in cystathionine or pyruvate, the final products of CBS 
and CSE enzymes, respectively.  
 
  (A) 
 
 (B) 
 
Figure 39- Enzyme kinetics. Reactions catalyzed by cystathionine beta 
synthase (A) and cystathionine gamma lyase (B). 
 
5.4.1. Sample preparation 
All reaction components were prepared in 10 mM sodium phosphate pH 8.2. 
A standard assay in a 5 mm glass tube was composed of the enzyme substrate, 
15
N,
13
C-L-Cysteine (125 µL, 1 mM), L-Homocysteine (125 µL, 1 mM) (added 
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only for CBS timecourse as co-substrate), DTT (0.5 µL, 1M), D2O (50 µL), 
enzyme (100 µL, 110 µM) and filled to a final volume of 500 µL with 10 mM 
sodium phosphate buffer pH 8.2 in a 5 mm NMR tube. In order to verify the 
enzyme kinetics in the presence of the potential inhibitor, all components above 
were put into a different tube, preincubating the selected compound IIa (125 µL, 
2.5 mM) with each enzyme. Similarly, another sample was prepared using the 
known CSE inhibitor, D,L-propargylglycine (PGG) (125 µL, 2.5 mM), instead of 
the compound IIa.  
5.4.2. NMR measurements 
NMR experiments were performed at 300 K on a Bruker AVANCE 
spectrometer operating at 800 MHz with TCI Cryoprobes. Initially, the isolated 
enzyme or the enzyme pre-incubated with the tested compounds was excluded 
from the sample as a control. This blank was used to tune the spectrometer, 
acquire a lock signal and shim the instrument before the reaction was started by 
removing the tube from the instrument, adding the enzyme (100 µL, 110 µM), 
mixing several times by inverting the tube and re-inserting the tube in the 
instrument. Data acquisition was initiated once a stable lock signal was achieved. 
The same set of experiments was carried out in the absence and in the 
presence of tested compound (compound IIa and PGG, separately), pre-incubated 
with each enzyme.  
For each sample, pseudo-2D experiments were collected in which the first 
increment of a 
13
C HSQC spectrum was acquired with a 5 minutes repetition time 
for a total of 60 spectra, using 
15
N,
13
C, L-Cysteine and unlabeled L-Homocysteine 
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as CBS substrate and 
15
N,
13
C, L-Cysteine as a unique substrate for CSE enzyme. 
Furthermore, 2D 
1
H,
13
C HSQC spectra were acquired before and after the enzyme 
reaction was completed.  
5.5. Results and Discussion II 
Pseudo 2D spectra allowed us to follow 
15
N,
13
C, L-Cysteine conversion into 
the final products. Two dimensional 
13
C HSQC spectra were collected before and 
after each experiment to further confirm the completeness of the reactions.  
The time course for CBS production of L-Cystathionine is presented in 
Figure 40. As shown, 
15
N,
13
C, L-Cysteine peaks (
1
H-NMR  3.05, CH2; 3.90, 
CH) were gradually decreasing until completely disappearance, while the product 
was growing up. Cystathionine peaks (
1
H-NMR  3.97, 3.15, 3.10) were not all 
detected, because of the unlabeled homocysteine contribution. 
With regard to the time course of CSE, Figure 41 clearly shows that 
15
N,
13
C, L-Cysteine peaks (
1
H-NMR  3.05, CH2; 3.90, CH) decrease in size 
until completely disappearance, whereas the product pyruvate increase (
1
H-NMR 
 2.4, CH3). 
Another set of experiments was carried out in the presence of compound II, 
pre-incubated with each enzyme. When compound IIa was incubated with CBS 
enzyme, there was no kinetic modification, with the complete conversion of L-
Cysteine into L-cystathionine (Figure 42). Figure 48 shows 3D graphics derived 
from all acquired 1D 
13
C HSQC spectra over time during CBS time course (A) 
and the kinetics in the presence of compound IIa (B); comparison of the resulting 
graphics showed no significant differences. 
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Conversely, the tested compound was able to inhibit the production of 
pyruvate catalyzed by CSE (Figure 43), proving to be a CSE selective inhibitor, 
as well as the known CSE inhibitor, D,L-propargylglycine (PGG). It is clearly 
evident in the Figure 49 representing 3D graphics derived from all acquired 1D 
13
C HSQC spectra over time during CSE timecourse (A) and the kinetics in the 
presence of compound IIa (B). 
To verify if it is a competitive reaction, at the end of the CSE time course 
with compound IIa, an excess of L-cysteine was added and the experiment was 
carried out again. As shown in Figure 50, the cysteine peaks were not decreased, 
demonstrating that the enzyme was not able to continue its work anymore and that 
it was a noncompetitive inhibition.       
When PGG was used in the enzyme reaction, the pyruvate peak did not 
increase, as expected. Surprisingly, the L-cysteine peaks decreased and new 
product peaks, at 3.92, 3.40, 3.25 ppm, different from pyruvate, appeared and 
progressively increased (Figure 44).      
Most likely the new peaks represent the cystine. A possible explanation is 
that the cystine was formed enzymatically and not chemically, because in the 
reducing environment for the presence of dithiothreitol (DTT), it would not be 
possible the cysteine oxidation and consequent formation of the disulfide bond, 
unless enzyme activity. 
To further verify the completeness of the reaction, two dimensional 
13
C 
HSQC spectra, acquired before and after each time course, were overlapped. 
Figure 45 shows the cysteine peaks (blue spectrum acquired before the reaction), 
appeared at 55 ppm in F1 and 3.90 ppm in F2 (CH) and at 25 ppm in F1 and 3.05 
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ppm in F2 (CH2) These peaks are absent in the 
13
C HSQC spectrum (red), 
acquired at the end of the reaction, confirming the completeness of reaction. In 
Figure 46 
13
C HSQC spectrum acquired after CSE time course with compound 
IIa, was shown. The persistence of cysteine peaks at the end of the reaction 
confirms that compound IIa is a selective CSE inhibitor, by blocking the 
formation of pyruvate with a different mechanism from PGG inhibition. When 
CSE timecourse with PGG is completed, 
13
C HSQC spectrum (shown in Figure 
47) was acquired. Pyruvate production was blocked (despite a very small amount 
was formed, as evidenced by the presence of pyruvate peak); however, cysteine 
peaks were decreased, converting mainly into cystine (peaks at 55 in F1 and 3.92 
ppm in F2; 32 ppm in F1 and 3.4 in F2; 32 ppm in F1 and 3.25 ppm in F2). This 
suggests that both compounds (IIa and PGG) inhibit CSE production of pyruvate, 
by acting through two different mechanisms of inhibition: the compound IIa 
prevents the CSE enzyme from binding to its substrate, inhibiting the conversion 
of L-cysteine into pyruvate; PGG also inhibits the formation of pyruvate, but L-
cysteine, not able to bind the active site, becomes substrate for another binding 
site, giving cystine as different product (Figure 51 A-C). 
 
 
 
 
 
 
 
85 
 
 
 
 
 
Figure 40 - CBS time course. Real-time monitoring of CBS forward reaction by 
13
C filtered 
1
H NMR. Representative first (blue) and last (red) spectra are shown. 
Spectra showing CBS conversion of L-cysteine to L-cystathionine. The first 
spectrum was obtained ~2 min after the addition of enzyme, and subsequently 59 
spectra were collected over a 300 min period.  
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Figure 41 - CSE time course. Real-time monitoring of CSE forward reaction by 
13
C filtered 
1
H NMR. Representative first (blue) and last (red) spectra are shown. 
Spectra showing CSE conversion of cysteine to pyruvate. The first spectrum was 
obtained ~2 min after the addition of enzyme, and subsequently 59 spectra were 
collected over a 300 min period. 
 
 
 
 
 
87 
 
 
 
 
 
Figure 42 - CBS time course with compound IIa. Real-time monitoring of CBS 
forward reaction by 
13
C filtered 
1
H NMR. Representative first (blue) and last (red) 
spectra are shown. Spectra showing CBS time course in the presence of 
compound IIa. The first spectrum was obtained ~2 min after the addition of 
enzyme, and subsequently 59 spectra were collected over a 300 min period. 
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Figure 43 - CSE time course with compound IIa. Real-time monitoring of CBS 
forward reaction by 
13
C filtered 
1
H NMR. Representative first (blue) and last (red) 
spectra are shown. Spectra showing CBS time course in the presence of 
compound IIa. The first spectrum was obtained ~2 min after the addition of 
enzyme, and subsequently 59 spectra were collected over a 300 min period. 
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Figure 44 - CSE time course with the inhibitor D,L-propargylglycine. Real-
time monitoring of CSE forward reaction by 
13
C filtered 
1
H NMR. Representative 
first (blue) and last (red) spectra are shown. Spectra showing CSE inhibition with 
D,L-propargylglycine. The first spectrum was obtained ~2 min after the addition 
of enzyme, and subsequently 59 spectra were collected over a 300 min period. 
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Figure 45 - CSE time course. 2D 
1
H,
13
C-HSQC spectra acquired before (blue 
peaks) and after (red peaks) the enzyme reaction. 
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Figure 46 - CSE time course with compound IIa. 2D 
1
H,
13
C-HSQC spectrum 
acquired at the end of the reaction in the presence of compound IIa.  
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Figure 47 - CSE time course with the inhibitor D,L-propargylglycine. 2D 
1H,
13
C-HSQC spectrum acquired at the end of the reaction in the presence of 
PGG.  
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A. 
B. 
Figure 48 - 3D graphics of CBS time course. A. CBS time course; B. CBS time 
course in the presence of compound IIa. 
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A.  
 
B. 
Figure 49 - 3D graphics of CSE time course. A. CSE time course; B. CSE time 
course in the presence of compound IIa. 
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A. 
B. 
Figure 50 - 3D graphics of CSE time course. A. CSE time course in the 
presence of compound IIa; B. CSE time course with L-Cysteine excess. 
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A. 
 
B. 
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C. 
Figure 51 - 3D graphics of CSE time course. A. CSE time course; B. CSE time 
course in the presence of PGG; C. Different prospective of CSE time course in 
the presence of PGG. 
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6. Conclusion 
In the last few decades, investigation of the pathophysiological and 
pharmacological roles of hydrogen sulfide has represented a challenging research 
field, which is still widely unexplored. 
It is noteworthy to highlight that H2S relevance is constantly growing within 
scientific environment and it is now accepted as a novel gasotransmitter.  
Many researchers are trying to address biological functions of this gaseous 
mediator but achievements in this field are still lacking of “proof-of-concept”, 
despite the large body of evidence available in the literature. 
Several H2S donors have been used for basic research and many drug 
candidates are in development. Among them, there are agents that either directly 
release H2S when in solution (NaHS, Na2S, Lawesson's reagent, GYY4137) or 
function as a precursor for endogenous H2S synthesis (N-acetylcysteine, L-
cysteine). 
Currently, NaHS is the prototypical example of a H2S-generating agent: it is 
most widely used H2S donor for experimental purposes. However, this salt is not 
suitable for clinical purposes, as the quick release of H2S may cause adverse 
effects, such as a rapid and excessive lowering of blood pressure. 
Therefore, the design, synthesis and characterization of novel H2S donors 
could enormously boost this research field.  
In this work, we identified an innovative scaffold for the non-enzymatic 
release of hydrogen sulphide, acting with a slow release kinetic to emulate which 
is realized in a physiological context. 
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Specifically, a small library of 1,2,4 thiadiazolidine 3,5 diones (THIA I-VII, 
table 4) was prepared through suitable synthetic routes and evaluated for their 
H2S-releasing properties. 
These compounds, exhibiting the kinetic profile of H2S-releasing agents, 
may be viewed as both powerful tools for basic studies and new potential 
pharmacotherapeutic agents for treatment of various diseases. 
Another main line of research deals with the synthesis of selective 
inhibitors. At the present stage the research in this field is impaired by the lack of 
pharmacological tools such as selective enzymatic inhibitors. In fact, these 
established inhibitors exhibit low potency, low selectivity and poor cell-membrane 
permeability.  
As such, we aimed to develop more specific and potent inhibitors of CBS 
and CSE towards H2S production. 
Therefore, in order to develop compounds that selectively regulate 
enzymatic activity, we preliminarily selected and tested commercially available 
cysteine surrogates. These molecules were modified with propargyl and n-butyl 
group and the synthetic compounds, obtained in our laboratory, were tested on rat 
aortic rings.  
The compound showing maximal inhibitory effects in this test was an 
oxothiazolidine derivative, dubbed compound IIa. The effects of this compound 
on the enzyme kinetics was further tested on the purified enzymes using a 
metabolomic approach based on nuclear magnetic resonance techniques. 
These studies clearly showed that compound IIa is a potent enzyme 
inhibitor of CSE, without affecting the CBS kinetics. Comparing its inhibitory 
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activity with that of the known selective CSE inhibitor, D,L-propargylglycine 
(PGG), a significant difference was revealed: when PGG was used, the enzyme 
was inhibited from producing pyruvate, ammonia and hydrogen sulphide, but 
surprisingly, it was still active and gave a new product, using cysteine as substrate. 
In contrast, the compound IIa inhibited the enzyme, keeping the concentration of 
substrate unaffected. 
This finding suggests the possibility of using lower doses of compound IIa 
compared to PGG, consequently reducing all possible adverse effects. 
The identification of this highly selective CSE inhibitor may help to better 
define the role of CSE vs CBS in the pathophysiology of the diseases where a role 
for the H2S pathway has been proposed. 
Furthermore, the development of such agents, particularly water-soluble, 
will allow us to evaluate the cross-talk of H2S pathways with other relevant 
pathways (e.g.,NO, COX). 
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